 
 
Protocol  H9X -MC-GBGE(a)  
 
 
A Randomized, Parallel -Arm, Double -Blind Study of Efficacy and Safety of Dulaglutide When 
Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus  
 
 
[STUDY_ID_REMOVED]  
 
 
Approval Date: 21 -Aug-2015  
H9X-MC-GBGE(a) Clinical Protocol  Page 1 
LY2189265   
  
Protocol H9X -MC-GBGE(a)  
A Randomized, Parallel -Arm, Double -Blind Study of Efficacy 
and Safety of Dulaglutide When Added to SGLT2 Inhibitors in 
Patients with Type 2 Diabetes Mellitus  
(AWARD -10: Assessment of Weekly Administ Ration of 
LY2189265 in Diabetes – 10) 
 
 
 
 
 
Dulaglutide (LY2189265)  
 
 
 
 
 
Eli Lilly and Company 
Indianapolis, Indiana [LOCATION_003] [ZIP_CODE]  
 
 
 
Protocol Electronically Signed and Approved by [CONTACT_11007]: 29 July 2015 
Amendment (a) Electronically Signed and Approved by [CONTACT_81098].  
 
 
 
 
Approval Date: 21 -Aug-2015 GMT  Confidential Information  
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copi[INVESTIGATOR_81058] (LY2189625), unless such persons are bound by a confidentiality agreement 
with Eli Lilly and Company or its subsidiaries.  
 
Note to Regulatory Authorities : This document may contain protected personal data 
and/or commercially confidential information exempt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA)  
Exemption [ADDRESS_88343] of the addition of once -weekly dulaglutide 1.5 mg or 0.75 mg to  
SGLT2 inhibitors, with or without concomitant use of metformin, on change from baseline in 
hemoglobin A1c ( HbA1c) at 24 weeks in patients with type 2 diabetes mellitus.  
H9X-MC-GBGE(a) Clinical Protocol  Page 2 
LY2189265   
  
Table of Contents  
Section  Page  
1. Protocol  Synopsis  ................................ ................................ ................................ ....................  9 
2. Introduction  ................................ ................................ ................................ ...........................  12 
2.1. Background  ................................ ................................ ................................ ......................  13 
2.2. Study  Rationale  ................................ ................................ ................................ ................  13 
3. Objectives  and Endpoints  ................................ ................................ ................................ ...... 14 
4. Study  Design  ................................ ................................ ................................ .........................  16 
4.1. Overview of  Study  Design  ................................ ................................ ...............................  16 
4.2. End of  Trial  Definition  ................................ ................................ ................................ .... 18 
4.3. Scientific Rationale for Study  Design  ................................ ................................ ..............  18 
4.4. Justification  for Dose  ................................ ................................ ................................ ....... 19 
4.5. Benefit/Risk  Assessment  ................................ ................................ ................................ . 19 
5. Study  Popul ation  ................................ ................................ ................................ ...................  20 
5.1. Inclusion Criteria  ................................ ................................ ................................ .............  20 
5.2. Exclusion Criteria  ................................ ................................ ................................ ............  22 
5.3. Screen  Failures  ................................ ................................ ................................ .................  24 
5.4. Lifestyle and/or  Dietary  Requirements  ................................ ................................ ............  24 
6. Treatment  ................................ ................................ ................................ ..............................  25 
6.1. Treatments  Administered  ................................ ................................ ................................ . 25 
6.2. Method of  Treatment  Assignment  ................................ ................................ ...................  25 
6.2.1. Selection and Timing  of Doses  ................................ ................................ ................  26 
[IP_ADDRESS].  Dulaglutide or  Placebo  Injections  ................................ ................................ ..... 26 
6.3. Blinding  ................................ ................................ ................................ ...........................  26 
6.4. Packaging  and Labelling  ................................ ................................ ................................ .. 27 
6.5. Preparation/Handling/Storage  ................................ ................................ ..........................  27 
6.6. Dose  Modification  ................................ ................................ ................................ ...........  28 
6.6.1. Special  Treatment Considerations  ................................ ................................ ...........  28 
[IP_ADDRESS].  Standards of  Medical  Care  ................................ ................................ ................  28 
[IP_ADDRESS].  Management of Increased  Hypoglycemia  Risk ................................ .................  28 
[IP_ADDRESS].  Management of Patients with Severe,  Persistent  
Hyperglycemia during the  Treatment  Period  ................................ ....................  29 
6.7. Treatment  Compliance  ................................ ................................ ................................ ..... 30 
6.8. Concomitant Therap y ................................ ................................ ................................ ...... 30 
6.8.1. Antihyperglycemia  Medications  ................................ ................................ ..............  31 
[IP_ADDRESS].  Allowed  Concomitant OAMs  ................................ ................................ ............  31 
[IP_ADDRESS].1.  SGLT2 Inhibitors  ................................ ................................ ...........  32 
H9X-MC-GBGE(a) Clinical Protocol  Page 3 
LY2189265   
  
[IP_ADDRESS].2.  Metformin  ................................ ................................ .......................  [ADDRESS_88344]  to Follow -Up ................................ ................................ ......................  38 
8. Study Assessments  and Procedures  ................................ ................................ .......................  39 
8.1. Efficacy Assessments  ................................ ................................ ................................ ...... 39 
8.1.1. Primary Efficacy  Assessments  ................................ ................................ .................  39 
8.1.2. Secondary  Efficacy  Assessments  ................................ ................................ .............  39 
8.1.3. Exploratory  Assessments  ................................ ................................ .........................  39 
8.1.4. Appropriateness  of Assessments  ................................ ................................ .............  40 
8.2. Adverse Events  ................................ ................................ ................................ ................  40 
8.2.1. Serious  Adverse  Events  ................................ ................................ ...........................  41 
[IP_ADDRESS].  Suspected Unexpected Serious  Adverse  Reactions  ................................ ...........  [ADDRESS_88345]  ................................ ................................ .......................  42 
[IP_ADDRESS].  Hypoglyc emia  and Hyperglycemia  ................................ .........................  42 
[IP_ADDRESS].  Pancreatitis  ................................ ................................ ..............................  42 
[IP_ADDRESS].  C-Cell Hyperplasia and  C-Cell Neoplasms  ................................ .............  43 
[IP_ADDRESS].  Cardiovascular  Events  ................................ ................................ .............  44 
[IP_ADDRESS].  Renal Events  ................................ ................................ ............................  44 
[IP_ADDRESS].  Allergic/Hypersensitivity  Reactions  ................................ .......................  44 
8.2.3. Complaint  Handling  ................................ ................................ ................................ . 44 
8.3. Treatment  of Overdose  ................................ ................................ ................................ .... 44 
8.4. Safety  Assessments  ................................ ................................ ................................ ..........  44 
8.4.1. Electrocardiograms  ................................ ................................ ................................ .. 44 
8.4.2. Blood Pressure and  Heart  Rate ................................ ................................ ................  45 
8.4.3. Laboratory  Tests  ................................ ................................ ................................ ...... 45 
8.4.4. Body Weight and Body  Mass Index  ................................ ................................ ........  45 
8.4.5. Safety  Monitoring  ................................ ................................ ................................ .... 45 
8.5. Pharmacokinetics  ................................ ................................ ................................ .............  46 
 
H9X-MC-GBGE(a) Clinical Protocol  Page 4 
LY2189265   
  
8.6. Pharmacodynamics  ................................ ................................ ................................ ..........  46 
8.7. Genetics  ................................ ................................ ................................ ...........................  46 
8.8. Biomarkers  ................................ ................................ ................................ ......................  46 
8.9. Health  Economics  ................................ ................................ ................................ ............  47 
9. Statistical Considerations and  Data  Analysis  ................................ ................................ ........  48 
9.1. Determination of  Sample  Size ................................ ................................ .........................  48 
9.2. General  Statistical  Considerations  ................................ ................................ ...................  48 
9.3. Treatment  Group  Comparability  ................................ ................................ .....................  49 
9.3.1. Patient Disposition  ................................ ................................ ................................ ... 49 
9.3.2. Patient Characteristics  ................................ ................................ .............................  50 
9.3.3. Concomitant Therapy  ................................ ................................ ..............................  50 
9.3.4. Treatment  Compliance  ................................ ................................ .............................  50 
9.4. Primary and Secondary  Analyses  ................................ ................................ ....................  50 
9.4.1. Primary Outcome Measure  and Analyses  ................................ ................................  50 
[IP_ADDRESS].  Additional Analyses of the  Primary  Outcome ................................ .........  50 
9.4.2. Secondary Outcome Measures  and Analyses  ................................ ..........................  51 
9.5. Safety  Analyses  ................................ ................................ ................................ ...............  52 
9.5.1. Study  Drug  Exposure  ................................ ................................ ...............................  52 
9.5.2. Adverse Events  ................................ ................................ ................................ ........  52 
9.5.3. Hypoglycemic  Epi[INVESTIGATOR_1841]  ................................ ................................ ..........................  52 
9.5.4. Hyperglycemic  Epi[INVESTIGATOR_1841]  ................................ ................................ .........................  53 
9.5.5. Special  Safety  Topi[INVESTIGATOR_1102]  ................................ ................................ ...............................  53 
[IP_ADDRESS].  Pancreas  Safety ................................ ................................ ........................  53 
[IP_ADDRESS].  Cardiovascular Safety  ................................ ................................ .............  53 
[IP_ADDRESS].  Thyroid  Safety  ................................ ................................ .........................  53 
[IP_ADDRESS].  Renal  Safety  ................................ ................................ ............................  53 
[IP_ADDRESS].  Allergic/Hypersensitivity  Reactions  ................................ .......................  53 
9.5.6. Laboratory  Analytes ................................ ................................ ................................ . 53 
9.6. Pharmacokinetic/Pharmacodynamic  Analyse s ................................ ................................  53 
9.7. Other  Analyses  ................................ ................................ ................................ ................  54 
9.7.1. Subgroup  Analyses  ................................ ................................ ................................ .. 54 
9.8. Interim  Analyses  ................................ ................................ ................................ ..............  54 
10. Study  Governance  Considerations  ................................ ................................ ........................  55 
10.1. Regulatory and Ethical Considerations, Including the  Informed  
Consent Process  ................................ ................................ ................................ ...............  55 
10.1.1.  Informed  Consent  ................................ ................................ .............................  55 
10.1.2.  Ethical  Review  ................................ ................................ ................................ . 55 
10.1.3.  Regulatory  Considerations  ................................ ................................ ...............  55 
H9X-MC-GBGE(a) Clinical Protocol  Page 5 
LY2189265   
  
10.1.4.  Investigator  Information ................................ ................................ ..........................  56 
10.1.5.  Protocol  Signatures  ................................ ................................ ................................ . 56 
10.1.6.  Final Report Signature  ................................ ................................ ............................  56 
10.2. Data  Quality  Assurance  ................................ ................................ ................................ ... 56 
10.2.1.  Data Capture System  ................................ ................................ ...............................  57 
10.3. Study and  Site Closure  ................................ ................................ ................................ .... 57 
10.3.1.  Discontinuation of  Study  Sites  ................................ ................................ ................  57 
10.3.2.  Discontinuation of  the Study  ................................ ................................ ...................  57 
11. References  ................................ ................................ ................................ ............................  58 
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88346] of Tables  
Table  Page  
Table  GBGE.1.  Objectives  and Endpoints  ................................ ................................ .................  14 
Table  GBGE.2.  Study Treatments and  Concomitant  Medications  ................................ .............  25 
Table GBGE.3.  Required Doses of Concomitant SGLT2 Inhibitors and Metformin  in 
Study GBGE for Patients Already Using  These Agents  ................................ .. 32 
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88347] of Figures  
Figure  Page  
Figure GBGE.1.  Illustration of study design for Clinical  Protocol  H9X -MC-GBGE.  ................  16 
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88348] of Appendices  
Appendix  Page  
Appendix  1. Abbreviations  and Definitions  ................................ ................................ ..........  61 
Appendix  2. Schedule  of Activities  ................................ ................................ .......................  64 
Appendix  3. Clinical Laboratory  Tests  ................................ ................................ .................  69 
Appendix  4. Hepatic Monitoring Tests for  Treatment -Emergent  Abnorm ality ....................  71 
Appendix  5. Sampling Summary  ................................ ................................ ..........................  72 
Appendix  6. Protocol GBGE World Health Organization Classification of  Diabetes  
and Diagnostic  Criteria  ................................ ................................ .....................  73 
Appendix  7. Protocol GBGE World Health Organization Standardized Protocols  for 
the Measurement of Height  and Weight  ................................ ...........................  74 
Appendix  8. Protocol Amendment H9X -MC-GBGE(a) Summary – A Randomized,  
Parallel -Arm, Double -Blind Study of Efficacy and Safety of 
Dulaglutide When Added to SGLT2 Inhibitors in Patients with Type  2 
Diabetes  Mellitus  ................................ ................................ ..............................  75 
H9X-MC-GBGE(a) Clinical Protocol  Page 9 
LY2189265   
  
1. Protocol  Synopsis  
Title of Study:  
A Randomized, Parallel -Arm, Double -Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 
Inhibitors in Patients with Type 2 Diabetes Mellit us (AWARD -10: Assessment of Weekly AdministRation of 
LY2189265 in Diabetes – 10) 
Rationale:  
Combined use of glucose -lowering pharmacological agents is common in patients with type 2 diabetes (T2D) and 
often includes 2, 3, or more classes of therapeutics. The sodium -glucose co -transporter 2 (SGLT2) inhibitors and 
glucagon -like peptide -1 receptor agonists (GLP -1 RAs) are indicated in similar populations and their combined use 
is of clinical interest; however, clinical data is currently limited.  
An important aspect of the concomitant treatment with these 2 classes of agents is a potential for additi ve or 
synergistic actions on blood glucose due to their complementary mechanisms of actions; SGLT2 inhibitors lower 
blood glucose by [CONTACT_81099], while GLP -1 RAs enhance glucose -mediated insulin 
secretion and also suppress glucagon. Similarly, both may lower body weight and blood pressure; therefore, 
combined use of these agents may provide T2D patients with a treatment regimen that is associated with an 
acceptable safety profile, in addition to clinically relevant glucose -lowering effects.  
It is also of particular interest to assess the overall tolerability of the combination therapy, including hemodynamic 
and renal parameters. SGLT2 inhibitors may cause volume depletion due to their osmotic effect in kidney tubules 
and may be associated with impairment in renal function. GLP -1 RAs may also cause loss of body fluid when 
severe, protracted vomiting occurs.  
Objectives/Endpoints:  
 
Objectives  Endpoints  
Primary: To demonstrate that once -weekly 
dulaglutide (1.5 mg and/or 0.75 mg) is superior to 
placebo as measured by [CONTACT_33308] A1c (HbA1c) at 
24 weeks (change from baseline) in patients with 
inadequately controlled T2D on concomitant SGLT2 
inhibitor therapy.   The cha nge in HbA1c from baseline to 
24 weeks  
Secondary: Key secondary efficacy objectives 
(controlled for type 1 error) are to compare dulaglutide  
1.5 mg and 0.75 mg to placebo at 24 weeks.   Proportion of patients with HbA1c target 
values of <7.0% at 24  weeks  
 The change in fasting blood glucose (FBG) 
(central laboratory) from baseline to 24  weeks  
 The change in body weight from baseline to 
24 weeks  
H9X-MC-GBGE(a) Clinical Protocol  Page 10 
LY2189265   
  
 
Summary of Study Design:  
 
Study H9X -MC-GBGE is a randomized, double -blind, placebo -controlled, parallel -arm, multicenter, Phase 3b trial 
that investigates the effect of the addition of once -weekly dulaglutide 1.5 mg or 0.75 mg to SGLT2 inhibitors, with 
or without concomitant use of  metformin, on glycemic control and safety over a 24 -week treatment period in 
patients with inadequately controlled T2D . 
Treatment Arms and Duration:  
 
After completing screening, a 1 -week lead -in period, and if necessary, a 12 -week stabilization period, pa tients will 
be randomized 1:1:[ADDRESS_88349] minimum -required doses of SGLT2 inhibitor (± metformin).  Study participants will be treated for  
24 weeks after r andomization.  
 
Number of Patients:  
 
The study will need 101completers per arm in order to have 90% probability of achieving statistical significance for 
either dulaglutide 1.[ADDRESS_88350] deviation of 1.2 %, a difference between dulaglutide and placebo of 0.6%, and a 2 -sided significance level 
of 0.025. Assuming that the dropout rate is 15% for the entire study period, the study will need to enroll at least 119 
patients in each arm for a total of 357 patien ts enrolled.  Assuming a screen fail rate of 40%, 595 patients will need 
to be screened to meet these enrollment number requirements.  
Statistical Analysis:  
 
Two analysis models will be used for the primary objective. The primary analysis will be mixed -model repeated 
measure (MMRM) analysis using restricted maximum likelihood (REML) with treatment, country, SGLT2 inhibitor 
dose (“low” vs. “high”), metformin use  (“yes” vs. “no”), visit and treatment -by-visit as fixed effects, baseline  
value as a covariate, and patient as random effect. An unstructured covariance structure will be used to model the 
within -patient errors. The secondary analysis for the primary obje ctive will be analysis of covariance (ANCOVA) 
using a similar model as described above with treatment, country, SGLT2 inhibitor dose (“low” vs. “high”), and 
metformin use (“yes” vs. “no”) as factors and baseline value as a covariate. Missing endpoints will  be imputed with 
the last (post -baseline) -observation -carried -forward (LOCF). For the key secondary continuous measures (body 
weight and FBG), both models (with HbA1c strata included), will also be used. The percent to goal, ie, the 
percentage of patients achieving target HbA1c of <7.0% at [ADDRESS_88351] for superiority of each of the 
dulaglutide doses versus placebo at 24 weeks for the following measures: (1) change from baseline in HbA1c, (2) 
change from baseline in FBG, (3) percent achieving HbA1c < 7.0%, and (4) change from baseline in body weight.  
The primary analysis population will be the intent -to-treat (ITT) population, defined as all patients randomized who 
have taken at least 1 dose. This is also the safety population . For the primary analysis, all available data up to 24 
weeks will be included except those collected after initiation of glucose -lowering rescue therapy. The primary 
analysis will be repeated with all available data included, including those collected aft er initiation of rescue therapy.  
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88352] number of measurements (HbA1c, percent to goal in HbA1c, FBG, and body weight) will also be evaluated 
in the Per Protocol population.  
H9X-MC-GBGE(a) Clinical Protocol  Page 12 
LY2189265   
  
2. Introduction  
Glucagon -like peptide -1 receptor a gonists (GLP -1 RAs) have been developed for use as 
monotherapy or in combination with 1 or more oral antihyperglycemia medications (OAMs) 
and/or insulin for treatment of type 2 diabetes mellitus (T2D) (By[CONTACT_28556] ® USPI, 2015; By[CONTACT_28557] ® 
USPI, 2015; Tanzeum™ USP I, 2015; Trulicity™ USPI, 2015; Victoza ® USPI, 2015). Expected 
adverse events (AEs) of the GLP -1 RA class are mostly those from the gastrointestinal (GI) 
system organ class. Dulaglutide is a once -weekly GLP -1 RA approved as a monotherapy or in 
combination with OAMs and/or insulin for treatment of T2D (Trulicity USPI, 2015). Based on 
the experience from completed dulaglutide trials, similar to the GLP -[ADDRESS_88353] common AEs associated with dulaglutide treatment. These AEs are mostly mild to 
moderate in severity, transient, and their incidence decreases over time. More information about 
the known and expected benefits, risks, serious adverse events (SAEs), and reasonably 
anticipated AEs of dulaglutide may be found in the Investigator’s Broc hure (IB).  
Inhibitors of the active sodium -glucose co -transporter 2 (SGLT2) are a new class of glucose - 
lowering agents that act by [CONTACT_81100]. The SGLTs are carrier 
proteins that are located in proximal or distal kidney tubul es and are involved in active 
reabsorption of glucose from the tubular fluid back into the bloodstream (Jardiance ® USPI, 
2014; Farxiga ® USPI, 2015; Invokana ® USPI, 2015).  There are two types of SGLTs, SGLT1 
and SGLT2; they differ in their binding capacity  and binding affinity for glucose. It has been 
shown that pharmacological inhibition of SGLT2 decreases blood glucose without increasing the 
risk of hypoglycemia, and reduces systolic blood pressure and body weight (Jardiance USPI, 
2014; Farxiga USPI, 2015 ; Invokana USPI, 2015). The effect of SGLT1 inhibition on urinary 
glucose loss is much smaller, and its contribution to blood glucose lowering is considered to be 
limited. The SGLT2 inhibitors are indicated as monotherapy or in combination with 1 or 2 othe r 
OAMs and/or insulin for treatment of T2D. The most commonly reported AEs with inhibitors of 
SGLT2 are urinary tract infections and female genital mycotic  infections.  
There are no published data from randomized clinical trials on the effects of combined use of 
SGLT2 inhibitors and GLP -1 RAs. Due to their mostly complementary mechanisms of action, 
except for opposing action on glucagon secretion, combined treatment with these agents may 
provide an option for patients with T2D that is effective for glucose lowering without increasing 
hypoglycemia risk, and may decrease body weight and blood pressure.  
Study H9X -MC-GBGE (GBGE; AWARD -10) is designed to assess the efficacy and  safety of 
dulaglutide versus placebo, both added to the existing therapy of a stable dose of SGLT2 
inhibitor (with or without a stable dose of metformin) in patients with T2D. The primary 
objective is to show superiority of the dulaglutide 1.5 -mg dose and /or dulaglutide 0.75 -mg dose 
to placebo for change from baseline in hemoglobin A1c (HbA1c) at [ADDRESS_88354] on the 
proportion of patients reaching HbA1c targ ets (<7.0%), body weight, and fasting blood glucose 
(FBG) at 24 weeks. The primary objective and all key secondary objectives will be analyzed 
using a family -wise strategy to control for type 1 error.  
H9X-MC-GBGE(a) Clinical Protocol  Page 13 
LY2189265   
  
2.1. Background  
A GLP -1 RA, dulaglutide is a biosynthetic fusion protein molecule produced using mammalian 
cell cultures, and consists of 2 identical, disulphide -linked chains, each containing an N -terminal 
glucagon -like peptide -1 (GLP -1) analogue sequence covalently link ed to a modified human 
immunoglobulin G4 (IgG4) heavy chain by a small peptide linker (Trulicity™ USPI, 2015).  
These structural features of the dulaglutide molecule (1) decrease the rate of clearance, (2) 
increase the duration of pharmacologic activity, (3 ) may reduce immunogenic potential, and (4) 
may decrease unwanted antibody -mediated effect or function (Barrington et al. 2011; Trulicity 
USPI, 2015).  
Dulaglutide exhibits GLP -1 mediated effects, including glucose -dependent potentiation of 
insulin secretio n, inhibition of glucagon secretion, delay of gastric emptying, and weight loss 
(Trulicity USPI, 2015). Preclinical and clinical experience to date support the use of dulaglutide 
as a once -weekly injection to improve glycemic control in patients with T2D ( Barrington et al. 
2011). Dulaglutide received regulatory approval in the [LOCATION_002] on [ADDRESS_88355]; however, clinical 
data are currently limited (Inzucchi et al. 2015).  
An important aspect of the concomitant treatment with these 2 classes  of agents is a potential for 
additive or synergistic actions on blood glucose due to their complementary mechanisms of 
action; SGLT2 inhibitors lower blood glucose by [CONTACT_81099], 
while GLP -1 RAs enhance glucose -mediated i nsulin secretion and also suppress glucagon 
(Jardiance USPI, 2014; By[CONTACT_81101], 2015; By[CONTACT_81102], 2015; Farxiga USPI, 2015;  
Invokana USPI, 2015; Tanzeum USPI, 2015; Trulicity USPI, 2015; Victoza USPI, 2015). 
Similarly, both may lower body weight and blo od pressure; therefore, combined use of these 
agents may provide T2D patients with a treatment regimen that is associated with an acceptable 
safety profile, in addition to clinically relevant glucose -lowering effects.  
It is also of particular interest to assess the overall tolerability of the combination therapy, 
including hemodynamic and renal parameters. Sodium -glucose co -transporter [ADDRESS_88356] in kidney tubules  and may be associated with 
impairment in renal function. It has been suggested that this excessive water loss in 
insulinopenic T2D patients may increase the risk of ketoacidosis in the absence of severe 
hyperglycemia. In patients taking a GLP -1 RA, the pr esence of vomiting or decreased appetite 
may be associated with changes to the patient’s volume status.  
H9X-MC-GBGE(a) Clinical Protocol  Page 14 
LY2189265   
  
3. Objectives and  Endpoints  
Table GBGE.1  shows the objectives and endpoints of the study.  
 
Table  GBGE.1.  Obje ctives and  Endpoints  
 
Objectives  Endpoints  
Primary  
To demonstrate that once -weekly dulaglutide (1.5 mg 
and/or 0.75 mg) is superior to placebo as measured by 
[CONTACT_13505]1c at 24 weeks (change from baseline) in patients 
with inadequately controlled T2D on concomitant 
SGLT2 inhibitor therapy.   
 The change in HbA1c fro m baseline to 
24 weeks  
Secondary  
Key secondary efficacy objectives (controlled for type 1 
error) are to compare dulaglutide 1.5 mg and 0.75 mg to 
placebo at 24 weeks  
 
 
 
 
 
Other secondary efficacy objectives are to compare 
dulaglutide 1.5 mg and 0.75 mg to placebo at 24 weeks  
 
 
 
 
 
 
Secondary safety objectives are to compare dulaglutide  
1.5 mg and 0.75 mg to placebo at 24 weeks   
 Proportion of patients with HbA1c target values 
of <7.0% at 24  weeks  
 The change in FBG (central laboratory) from 
baseline to 24  weeks  
 The change in body weight from baseline to 
24 weeks  
 
 
 Proportion of patients with HbA1c target values 
of ≤6.5% at 24  weeks  
 The change in 6 -point SMPG profile from 
baseline to 24  weeks  
 The change in fasting glucagon from baseline 
to 24  weeks  
 
 
Incidence of:  
 Treatment -emergent adverse events  (TEAEs)  
 Early discontinuations due to  AEs 
 Adjudicated cardiovascular and pancreatic  AEs 
 Thyroid neoplasms  AEs 
 AEs related to kidney failure,  eGFR  
 Systemic hypersensitivity  AEs 
 Local injection site  reactions  
 The change in systolic and diastolic blood 
pressure, heart rate, and lipi[INVESTIGATOR_81059] 
24 weeks  
 Incidence and rate of hypoglycemic  epi[INVESTIGATOR_1841]  
 Ketoacidosis, and initiation of rescue  therapy 
for severe persistent  hyperglycemia  
H9X-MC-GBGE(a) Clinical Protocol  Page 15 
LY2189265   
  
 
Objectives and Endpoints  
Objectives  Endpoints  
Exploratory  
Exploratory efficacy objectives are to compare 
dulaglutide 1.5 mg and 0.75 mg to placebo at 24 weeks   
 Proportion of patients meeting the composite 
endpoint of HbA1c <7.0%, no weight gain, and 
no documented symptomatic  hypoglycemia  
 
 Proportion of patients meeting the composite 
endpoint of HbA1c <7.0%, body weight  loss 
>5%, and no documented symptomatic 
hypoglycemia  
Abbreviations: AE = adverse event; eGFR = estimated glomerular filtration rate; FBG = fasting blood glucose; 
HbA1c = hem oglobin A1c; SGLT2 = sodium -glucose co -transporter 2; SMPG = self -monitored plasma glucose; 
T2D = type 2 diabetes.  
H9X-MC-GBGE(a) Clinical Protocol  Page 16 
LY2189265   
 24 weeks  24 week  Treatment  Period  
Once -weekly  placebo+SGLT2  inhibitor (±metformin)  
Dulaglutide  0.75 mg/week+SGLT2  inhibitor  (±metformin)  
 
Dulaglutide 1.5 mg/week+SGLT2 inhibitor (±metformin)  1 week 
1 week 
11 weeks 
1 week  
4. Study  Design  
4.1. Overview of Study  Design  
Study GBGE is a randomized, double -blind, placebo -controlled, parallel -arm, multicenter, 
Phase 3b trial that investigates the effects of the addition of once -weekly dulaglutide 1.5 mg or  
0.75 mg to SGLT2 inhibitors, with or without concomitant use of metfo rmin, on glycemic 
control and safety in patients with inadequately controlled T2D.  
Figure GBGE.1  illustrates the study design.  
 
Study  
Period I  Study Period II   
Study Period III  
 
- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
Visit  1  2 3 4 5 6 7 8 9 10 11 
Week  -(2-14) -(1-13) -12    -1 0 2 4 8 12 18 24 
 
  
Randomization  End of Treatment  Period  
Abbreviations: OAM = oral antihyperglycemia medication; SGLT2 = sodium -glucose 
co-transporter 2.  
a Patients who require adjustment of their OAM regimen to meet eligibility criteria will 
implement treatment changes during the lead -in period (between Visit 2 and Visit 3), all 
other patients will continue with their prestudy regimen without changes.  
b Patients who adjust their OAM regimen during lead -in and/or need to stabilize the 
regimen will perform Visit 3 (end of lead -in) as their next visit and will then enter 1 to 
12-weeks stabilization, as needed. All other patients will skip Visit 3 and 4 and will 
perform Visit 5 as their next visit (approximately 1 week after Visit 2).  
 
Figure  GBGE.1.  Illustration of study design for Clinical Protocol  H9X-MC-GBGE.  
 
 
Study Periods  
For each study period and each visit, study procedures are provided in the Schedule of  Activities 
(Appendix 2 ). 
Screening 
Lead-Ina 
Stabilizationb 
H9X-MC-GBGE(a) Clinical Protocol  Page 17 
LY2189265   
  
 
Study Period I:  Screening (Visit 1)  
The purpose  of Visit  1 is to initiate  the assessment  of patient  eligibility  for participation  in the 
trial. Patients who meet all applicable inclusion criteria and none of the applicable exclusion 
criteria at Visit 1 (Section 5.1) will proceed to Visit 2 using the same OAMs (type and  dose).  
Study Period II:  Lead -in and Stabilization (Visits 2 to 4)  
The purpose of Visit 2 is to confirm patient eligibility, assess the need for stabilization of the 
OAM regimen, and provide trainings on study procedures. The need for stabilization of a 
patient’s OAM regimen should be based on the requirements for minimum  required and stable 
doses of SGLT2 inhibitors and metformin (see Section 5.1 and Section 6.8.1 ). 
Those patients who meet all enrollment requirements for treatment with stable and minimum 
requir ed doses of SGLT2 inhibitor and metformin at Visit [ADDRESS_88357] blood drawn for baseline 
HbA1c at this visit, followed by a 1 -week lead -in using the same treatment regimen (same OAM 
type and dose).  They will then proceed to Visit 5 (randomization visit).  
For patients not meeting dose requirements for allowed OAMs at Visit 2, or who require OAM 
regimen adjustments for other reasons, the investigator will advise the patient on how to adjust 
the OAM regimen between Visit 2 and 3 to meet the study requirements (see Section 6.8.1  for 
details). Those patients not accepting required changes will be considered as ineligible and will 
be discontinued immediately from the trial.  
The patients whose OAM regimen has been changed between Visi t 2 and 3 or whose doses of 
SGLT2 inhibitor and/or metformin prior to Visit [ADDRESS_88358] 1 to 12 weeks  
(±3 days), that is, until the time these re quirements are met. A blood sample for baseline HbA1c 
for patients who need stabilization will be drawn at Visit 4, approximately 1 week prior to  
Visit 5.  They will then proceed to Visit 5 (randomization visit).  
At Visit 2, eligible patients will receive training on study procedures (Schedule of Activities, 
Appendix 2 ) including the self -monitoring of plasma glucose (SMPG) plan (daily fasting plasma 
glucose and weekly 4 -point SMPG profile [consisting of fasting, pre -lunch, p re-dinner, and 
bedtime PG measurements]), 6 -point SMPG profile (before and 2 hours after each main meal), 
lifestyle treatment measures (Section 5.4), signs and symptoms and treatment of hyperglycemia 
(Section [IP_ADDRESS] ) and hypoglycemia (Section [IP_ADDRESS] ), and use of the study diary.  Single -dose 
pen (SDP) injector training will be completed with the demonstrator device, which does not 
include a needle.  
Study Period II I:  Randomization and Treatment Period (Visits 5 through 11)  
At Visit 5, investigators will first review the diary and assess patient eligibility. Patients with 
baseline HbA1c <7.0% or >9.5% will be excluded. Those patients who continue to be eligible 
will be randomized to 1 of the following treatment groups in a blinded fashion: (1) once -weekly 
dulaglutide 1.5 -mg injection, (2) once -weekly dulaglutide 0.75 -mg injection, or (3) once -weekly 
placebo injection (1:1:1 randomization ratio). Patients should injec t their first dose of study drug 
while in the clinic for Visit 5.  
H9X-MC-GBGE(a) Clinical Protocol  Page 18 
LY2189265   
  
 
Study participants will be treated for 24 weeks (treatment period). Study procedures for each 
visit are provided in the Schedule of Activities ( Appendix 2 ). 
Participants are required to continue using their concomitant OAMs throughout the treatment 
period. Discontinuation of these medications or changes in their dose is not permitted, except in 
situations where dose a djustment or complete discontinuation is required per country -specific 
label or when allowed per study protocol, for example, in the case of hypoglycemic epi[INVESTIGATOR_1841] (see 
Sections [IP_ADDRESS]  and [IP_ADDRESS]). 
Patients who develop persistent, severe hyperglycemia based on pre -specified thresholds (see 
Section [IP_ADDRESS] ) will continue administering study drug and will receive a new glucose -lowering 
intervention (rescue) based on  the clinical judgment of the investigator. These patients, as well 
as those who receive rescue therapy after discontinuation of study drug due to an AE or any 
other reason, will be asked to perform all study visits to collect planned efficacy and safety 
measurements.  
Those patients who are unable or unwilling to continue in the study because of an AE (see 
Section 7.1.2  for details) or any other reason, will perform an early termination (ET) visit as their 
final study visit (f or procedures at the ET visit , see the Schedule of Activities [ Appendix 2 ]). If 
the patient is discontinuing during an unscheduled visit, that visit should be performed as the ET 
visit. If the patient is discontinuing durin g a scheduled visit, that visit should be considered the 
ET visit.  
4.2. End of Trial  Definition  
End of the trial is the date of the last visit at which data for the primary analysis are collected for 
the last patient ( Appendix 2 ). 
4.3. Scientific Rationale for Study  Design  
This trial is designed to be consistent with recommendations provided in a position statement of 
the American Diabetes Association and the European Association for the study of Diabetes 
“Management of Hyperglycemia i n Type 2 Diabetes: A Patient -Centered Approach” (Inzucchi et 
al. 2015). Placebo comparator was chosen because it will enable characterization of efficacy and 
safety effects of dulaglutide when added to existing therapy with SGLT2 inhibitors, with or 
withou t metformin. Compared to a design which utilizes active comparator, comparison to 
placebo will allow assessment of the effect attributable to dulaglutide alone, which is of 
importance especially for the safety aspect of the combined use. The results are ex pected to 
enable physicians to choose patients suitable for the combination therapy in the clinical setting.  
To protect the safety of patients in the placebo arm who will enter Study GBGE with HbA1c 
above the <7% target, several design features are introdu ced for this purpose: (a) short trial 
duration (24 week -long treatment period), (b) exclusion of patients considered to have 
unacceptably high baseline HbA1c (>9.5%), and (c) additional glucose -lowering intervention 
(rescue) for patients with unacceptably high glycemia during the treatment period.  
Allowed concomitant medications are chosen because the combined use of dulaglutide with 
SGLT2 inhibitors is of significant clinical interest, but available clinical data are very limited.  
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88359] that c ommonly occurs with cross -over designs, while the proposed randomization scheme 
with stratification is included to minimize between -group heterogeneity.  The planned duration 
of treatment (24 weeks) is considered appropriate as the full effect of randomiz ed treatments on 
blood glucose is expected after approximately [ADDRESS_88360] trials (Dungan et al. 2014; Giorgino et al. 2014; Nauck et al. 
2014; Umpi[INVESTIGATOR_81060]. 2014; Wysham et al. 2014; Bl onde et al. 2015). The additional [ADDRESS_88361] of a treatment regimen on blood glucose and has been shown to be a reliable 
predictor of the long -term outcomes of diabetes (DCCT 1993; [LOCATION_006]PDS 1998).  Other key 
efficacy measures (propo rtion of patients with HbA1c <7%, body weight change, and FBG) are 
standard clinical parameters that are relevant for patients and physicians when assessing the 
effects of treatment in the clinical setting. Similarly, other efficacy and safety measures are  
standard for trials that evaluate glucose -lowering agents and are relevant in clinical decision - 
making.  
The statistical plan will include a graphical testing scheme to strongly control for type 1 error 
and will be applied in the analysis of the primary a nd the key secondary objectives. This 
approach has been well studied in the scientific literature and has been accepted by [CONTACT_81103] (Bretz et al. 2009).  
4.4. Justification for  Dose  
The approved Product Information for dulaglutide includes 2 approved doses, 1.5 and 0.75 mg 
once weekly (Trulicity™ Summary of Product Characteristics [SPC], 2014; Trulicity USPI, 
2015). Doses of SGLT2 inhibitors and metformin are chosen based on the appro ved regulatory 
labeling for these agents.  
4.5. Benefit/Risk  Assessment  
More information about the known and expected benefits, risks, SAEs, and reasonably 
anticipated AEs of dulaglutide are to be found in the IB, US prescribing information (USPI), and 
SPC.  
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88362] study visit.  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, are not permitted.  
 
5.1. Inclusion  Criteria  
Patients are eligible to be included in the study only if they meet all of the followin g criteria at 
study entry (Visit 1), and/or, when explicitly indicated below for specific criteria, at other visits 
during the lead -in/stabilization period (Visits 2 -5): 
[1] are men or non -pregnant women aged ≥18 years at  screening;  
[2] have  T2D (based  on the World Health  Organization’s  [WHO]  diagnostic 
criteria [ Appendix  6]); 
[3] have been treated with an SGLT2 inhibitor, with or without metformin, for at 
least 3 months prior to study entry (minimum required doses for that period 
for allowed SGLT2 inhibitors: empagliflozin 10 mg, dapagliflozin 5 or 10 mg 
[per country -specific label], canagliflozin 100 mg [see also Table GBGE.3  for 
details]); minimum required dose for metformin, if used, is ≥1500 mg/day an d 
must be reached by [CONTACT_4838] 3 (or highest tolerated dose which is acceptable with 
documented GI intolerability, see Section [IP_ADDRESS].2  for further  details);  
[4] daily doses of all allowed OAMs must have been stable for at least 12 weeks 
(±3 days) prior to randomization at Visit 5 (study enrollment); daily doses of 
SGLT2 inhibitor and metformin, if used, will be considered stable during this 
period  if: 
[a] all prescribed daily doses were in the range between the minimum - 
required dose (see Inclusion Criterion [3]) and maximum -approved dose 
per country -specific label;  and 
[b] >90% of prescribed daily doses were equal to the dose at Visit  5; 
[5] have HbA1c ≥7.0% and ≤ 9.5% at study entry ( Visit 1 ) and at Visit 2 for 
patients without stabilization; HbA1c ≥7.0% and ≤9.5% at study entry 
(Visit 1) and Visit 4 for patients with  stabilization;  
[6] have body mass index (BMI) ≤45 kg/m 2 and agree to not initiate a diet and/or 
exercise program during the study with the intent of reducing body weight 
other than the lifestyle and dietary measures for diabetes treatment (see 
Section  5.4); 
[7] are able and willing to  administer once -weekly  injections;  
[8] in the investigator’s opi[INVESTIGATOR_1649], are well motivated, capable, and willing  to: 
H9X-MC-GBGE(a) Clinical Protocol  Page 21 
LY2189265   
  
[a] perform finger -stick plasma glucose (PG) monitoring including 
scheduled daily PG profile with up to 6 measurements in 1  day; 
[b] learn how to self-inject  treatment,  as required  for this protocol  (visually 
impaired persons who are not able to perform the injections must have 
the assistance of a sig hted individual trained to inject the study drug; 
persons with physical limitations who are not able to perform the 
injections must have the assistance of an individual trained to inject the 
study  drug);  
[c] maintain a study diary, as required for this protocol;  
[9] Women of childbearing potential participating must agree to remain abstinent, 
use [ADDRESS_88363] dose of study  drug.  
[a] Women of childbearing potential must test negative for pregnancy prior 
to initiation  of treatment  as indicated  by a negative  serum  pregnancy  test 
at the screenin g visit ( Visit 1 ) followed by a negative urine pregnancy 
test within 24 hours prior to exposure ( Visit  5). 
[b] Either 1 highly effective method of contraception (eg, combined oral 
contraceptive pi[INVESTIGATOR_81061] -pi[INVESTIGATOR_4382], NuvaRing ®, implantable contraceptives, 
injecta ble contraceptives [such as Depo -Provera ®], intrauterine devices 
[such as Mirena ® and ParaGard ®]) or a combination of 2 effective 
methods of contraception (eg, male condom with spermicide, female 
condom with spermicide, diaphragm with spermicide, cervical sponge, 
cervical cap with spermicide) will be used.  The patient may choose to 
use a double -barrier method of contraception. Each barrier method must 
include  use of a spermicide  (ie, condom  with spermicide,  diaphragm  with 
spermicide, female condom with spermicide). Note: the use of male and 
female condoms as a double barrier method is not considered acceptable 
due to the high failure  rate when  these  methods  are combined.  
[c] Women must not be  breastfeeding.  
Women not of ch ildbearing potential may participate and are defined as:  
[a] infertile due to surgical sterilization (hysterectomy, bilateral 
oophorectomy, or tubal ligation), congenital anomaly such as Mullerian 
agenesis;  or 
[b] postmenopausal woman at least [ADDRESS_88364] uterus, 
who has not taken hormones or oral contraceptives within 1 year,  AND  
i) who has had either cessation of menses for at least 1 year,  OR 
ii) 6 months of spontaneous amenorrhea with follicle -stimulating 
hormone >40 mIU/mL (central lab; Appendix  2) 
H9X-MC-GBGE(a) Clinical Protocol  Page 22 
LY2189265   
  
Men participating are not required to use contraception during the study. 
Specific local government requirements that require contraception during the 
study are to be complied with to participate.  
[10] have given written and informed consent to participate in this study in 
accordance with local regulations and the ethical review board (ERB) 
governing the study  site. 
 
5.2. Exclusion  Criteria  
Patients will be excluded from the study if they meet any of the foll o wing criteria at Visit 1 
(study entry), and/or when explicitly indicated below for specific criteria, at other visits during 
the screening and lead -in/stabilization periods (Visits 2 -5): 
[11] have type 1 diabetes  mellitus;  
[12] have been treated with ANY other OAM s (other than SGLT2 inhibitors and 
metformin), GLP -1 RA, pramlintide or insulin 3 months prior to study entry, 
or between study entry and Visit 5 ; or initiate metformin between study  entry 
and Visit 5 ; short -term use of insulin for acute care (≤14 days) du ring the 3 - 
month period prior to entry is not  exclusionary;  
[13] have any condition that is a contraindication for use of the GLP -1 RA class or 
the SGLT2 inhibitor class (per country -specific labels) at study entry or 
develop such condition between study entry  and Visit  5; 
[14] for patients using metformin, if a condition that is a contraindication for its 
use develops between Visit 3 and Visit  5; 
[15] discontinue therapy with SGLT2 inhibitors any time prior to Visit 5 and/or 
metformin, if used, between Visit 3 and Visit 5 , based on the Exclusion 
Criteria  described  under  [13] and [14] above,  or any other  reason;  
[16] have a history of ≥1 epi[INVESTIGATOR_81062]/coma prior 
to study  entry;  
[17] have  a history  of hypoglycemia  unawareness  within  the 6 months  prior  to 
study  entry;  
[18] have been treated with drugs that promote weight loss (eg, Saxenda ® 
[liraglutide 3.0 mg], Xenical ® [orlistat], Meridia ® [sibutramine], Acutrim ® 
[phenylpropanolamine], Sanorex ® [mazindol], Adipex ® [phentermine], 
BELVIQ ® [lorcaserin], Qsymia™ [phentermine/topi[INVESTIGATOR_81063]], or 
similar over -the-counter [OTC] medications [eg, allī ®]) or have received a 
diet and/or exercise program with the intent of reducing body weight  other 
than the lifestyle and dietary measures fo r diabetes treatment (see Section 5.4) 
within 3 months prior to study entry or between study entry and Visit  5; 
H9X-MC-GBGE(a) Clinical Protocol  Page 23 
LY2189265   
  
[19] are receiving chronic (>14 days) systemic glucocorticoid therapy (excluding 
topi[INVESTIGATOR_2855], intraocular,  intranasal, intra -articular, or inhaled preparations) any 
time between entry and Visit [ADDRESS_88365] received such therapy within 1  month 
prior to study  entry;  
[20] have had any of the following cardiovascular (CV) conditions within  
2 months prior to study entry: acute myocardial infarction (MI), [LOCATION_001] 
Heart Association (NYHA) Class III or Class IV heart failure, or 
cerebrovascular accident (stroke);  
[21] have  a known  clinically  significant  gastric  emptying  abnormality  (eg, severe 
diabetic gastroparesis or gastric outlet obstruction) at study entry, or have 
undergone bariatric surgery (gastric by[CONTACT_14720], sleeve gastrectomy, 
adjustable gastric band or biliopancreatic diversion with duodenal switch) in 
the past;  
[22] have  acute  or chronic  hepatitis,  signs  and symptoms  of any other  liver disease 
other than nonalcoholic fatty liver disease (NAFLD), or alanine transaminase 
(ALT) level >2.5 times the upper limit of the reference range, as determined 
by [CONTACT_81104]; patients with NAFLD are eligible for 
participation in this  trial;  
[23] had chronic or acute pancreatitis any time prior to study  entry;  
[24] have an estimated glomerular filtration rate (eGFR) <45 mL/min/1.73m 2, 
calculated by [CONTACT_81105] -Epi[INVESTIGATOR_623] ( CKD -EPI) 
equation, as determined by [CONTACT_81106] 2; 
[25] have evidence of a significant, uncontrolled endocrine abnormality (eg, 
thyrotoxicosis, adrenal crisis) at study entry, in the opi[INVESTIGATOR_8598] e investigator;  
[26] have any self or family history of type 2A or type 2B multiple endocrine 
neoplasia (MEN 2A or 2B) in the absence of known C -cell hyperplasia  (this 
exclusion includes patients with a family history of MEN 2A or 2B, whose 
family history for the syndrome is rearranged during transfect [RET] - 
negative; the only exception for this exclusion will be for patients whose 
family members with MEN 2A or 2B have a known RET mutation and the 
potential patient for the study is negative for the RET  mutatio n); 
[27] have any self or family history of medullary C-cell hyperplasia, focal 
hyperplasia, carcinoma (including sporadic, familial, or part of MEN 2A or 
2B syndrome);  
[28] have a serum calcitonin ≥20 pg/mL as determined by [CONTACT_81107];  
[29] have evidence of a significant, active autoimmune abnormality  (eg, lupus, 
rheumatoid arthritis) at study  entry;  
H9X-MC-GBGE(a) Clinical Protocol  Page 24 
LY2189265   
  
[30] have  a history  of transplanted  organ  (corneal  transplants  [keratoplasty]  are 
allowed);  
[31] have  a history  of an active  or untreated  malignancy,  or are in remission  from  a 
clinically significant malignancy (other than basal or squamous cell skin 
cancer, in situ carcinomas of the cervix, or in situ prostate cancer) during the 
last 5 years prior to study  entry;  
[32] have a history of any other  condition (eg, known drug or alcohol abuse or 
psychiatric disorder) at study entry, that, in the opi[INVESTIGATOR_15863], 
may preclude  the patient  from  following  and completing  the protocol;  
[33] have  any hematologic  condition  that may interfere  with HbA1c  measurement 
(eg, hemolytic anemias, sickle -cell disease) at study  entry;  
[34] are investigator -site personnel directly affiliated with this study and/or their 
immediate families; immediate family is defined as a spouse, parent, child,  or 
sibling,  whether  biolo gical  or legally  adopted;  
[35] are Lilly  employees;  
[36] have participated within the last [ADDRESS_88366] has a long 
half-life, 3 months  or 5 half-lives  (whichever  is longer)  should  have  passed;  
[37] are currently enrolled in any other clinical trial involving an investigational 
product or any other type of medical research judged not to be scientifically or 
medically compatible with this  study;  
[38] have  previously  screen  failed,  withdr awn,  discontinued  or completed  this 
study  or been  randomized  in any other  study  investigating  dulaglutide.  
 
5.3. Screen  Failures  
Individuals who do not meet the criteria for participation in this study (screen failure) may not be 
re-screened.  
 
5.4. Lifestyle  and/or Dietary  Requirements  
Per the Schedule of Activities ( Appendix 2 ), qualified medical staff will provide diabetes 
management  counseling,  which  includes  diet, exercise,  and education  about  the signs,  symptoms, 
and treatment of hypoglycemia, should it occur. Patients should continue their usual exercise 
habits and generally follow a stable meal plan (with consistent meal size and time of day) 
throughout the course of the study.  Instruction on how to as sess carbohydrate content and 
caloric content of meals may be incorporated into the counseling. Dietary counseling may be 
reviewed throughout the study, as  needed.  
H9X-MC-GBGE(a) Clinical Protocol  Page 25 
LY2189265   
  
6. Treatment  
6.1. Treatments  Administered  
This study involves a comparison of dulagl utide 1.5 mg and dulaglutide 0.75 mg versus placebo, 
given once weekly as a subcutaneous injection in patients with T2D who are already treated with 
a stable dose of SGLT2 with or without stable dose of metformin. Table GBGE. 2 shows the 
treatment regimens.  
Table GBGE.2.  Study Treatments and Concomitant  Medications  
Name  [CONTACT_81154]  1.5 mg  Once weekly  Single -dose pen  Subcutaneous injection  
Dulaglutide  0.75 mg  Once weekly  Single -dose pen  Subcutaneous injection  
Comparator  
Placebo   
Placebo   
Once weekly   
Single -dose pen   
Subcutaneous injection  
Concomitant SGLT2 inhibitor for all treatment arms  
Canagliflozin  100 mg or 300 mg  Once daily  Tablet  Oral 
Dapagliflozin  5 mg or 10 mg  Once daily  Tablet  Oral 
Empagliflozin  10 mg or 25 mg  Once daily  Tablet  Oral 
Concomitant metformin for all treatment arms  
 
Metformin  1500 mg to  3000  mga Variable  Tablet/Liquid  Oral 
Abbreviations:  GI = gastrointestinal; SGLT2 = sodium -glucose co -trans porter  2. 
a     Range between minimum required dose of  ≥1500 mg/day (lower [or highest tolerated] dose is acceptable with  
documented GI intolerability) and maximum approved dose for metformin per country -specific label. 
Maximum approved dose may vary across labels.  
 
The investigator or his/her designee is responsible for the following:  
 explaining  the correct  use of the investigational  agent(s)  to the patient  or patient 
representative,  and SDP training  with a demonstration  device  
 explaining the correct use of concomitant SGLT2 inhibitors and metformin (if 
used) to the patient, including any contraindications and appropria te dosing  per 
country -specific labeling  
 verifying  that instructions  described  above  are followed  properly  
 maintaining accurate records of investigational product dispensing and  collection  
Patients should return all unused study drug to the site according t o the Schedule of Activities 
(Appendix 2 ). The patients should be instructed to discard all used SDPs in a closeable, 
puncture -resistant container, and dispose according to local regulations. Sites may be authorized 
to destr oy used and unused SDPs locally per applicable local or national requirements.  
6.2. Method of Treatment  Assignment  
Patients who meet all criteria for enrollment will be randomized to double -blind treatment at 
Visit 5.  Assignment to treatment groups will be determined by a computer -generated random  
H9X-MC-GBGE(a) Clinical Protocol  Page 26 
LY2189265   
  
 
sequence using an interactive web -response system (IWRS). The IWRS will be used to assign 
cartons containing double -blind investigational product to each patient. Site personnel will 
confirm that they have located the correct cartons by [CONTACT_45342] a confirma tion number found on 
the carton label into the IWRS.  
Block randomization will be used at the country level. Patients will be randomized in a 1:1:1 
ratio. Stratification for baseline HbA1c (≤8.0%, >8.0%), dose of SGLT2 inhibitor (“low” or 
“high”), and metfo rmin use (“yes” or “no”) will be used to mitigate against baseline 
heterogeneity between treatment groups. For the purpose of patient stratification, low dose of 
SGLT2 inhibitor is defined as the lowest dose approved in any of the participating countries 
(canagliflozin 100 mg, dapagliflozin 5 mg, empagliflozin 10 mg); high dose is defined as any 
dose higher than the low dose.  
6.2.1.  Selection and Timing of  Doses  
Details of the dosing strategy and administration timing for injectable study drug that are 
provided in  this section and the following sections are designed to achieve HbA1c  <7.0% 
without  hypoglycemia,  a standard  treatment  goal in this population.  
[IP_ADDRESS].  Dulaglutide or Placebo  Injections  
All patients will inject study drug subcutaneously in the abdomen or thigh us ing the injection 
supplies provided; a caregiver may administer the injection in the patient’s upper arm. A new 
SDP will be used for each injection.  
Study drug will be administered once weekly. It is recommended that patients inject the study 
drug at appro ximately the same time of day on the same day each week. If the injection is not 
given on the scheduled day, the missed dose should be given as soon as possible after the 
scheduled day if there are at least 3 days (72 hours) until the next injection. If fe wer than [ADDRESS_88367] of emergency codes generated by a computer drug -labeling system. This option 
may be used ONLY if the patient’s well -being requires knowledge of the patie nt’s treatment 
assignment.  All calls resulting in an unblinding event are recorded and reported by [CONTACT_8784].  
If an investigator, site personnel performing assessments, or patient is unblinded, the patient 
must be discontinued from the study. In cases where there are ethical reasons to have the patient 
remain in the study, the investigator must obtain specific app roval from a Lilly clinical research 
physician (CRP) for the patient to continue in the study.  
H9X-MC-GBGE(a) Clinical Protocol  Page 27 
LY2189265   
  
 
In case of an emergency, the investigator has the sole responsibility for determining if unblinding 
of a patient’s treatment assignment is warra nted. Patient safety must always be the first 
consideration in making such a determination. If the investigator decides that unblinding is 
warranted, the investigator should make every effort to contact [CONTACT_81108] 
a patient’s treatme nt assignment. If a patient’s treatment assignment is unblinded, Lilly must be 
notified immediately.  
6.4. Packaging and  Labelling  
The sponsor will provide dulaglutide and placebo in SDPs, which will be dispensed via an 
IWRS. Each SDP (0.75 mg dulaglutide in 0.5  mL OR 1.5 mg dulaglutide in 0.5 mL OR placebo 
in 0.5 mL) is packaged in cartons of 4 pens.  Each carton contains a 4 -week supply, as each pen 
is a weekly dose.  
Clinical trial materials will be labeled according to the country’s regulatory requirements.  
 
6.5. Preparation/Handling/Storage  
The study site must store the SDP cartons in a locked and secure environment. The SDPs must 
be refrigerated (not frozen) at 2°C to 8°C until use. Dry ice should not be used for cooling.  
Patients will be provided with cartons con tain ing 4 dulaglutide or placebo SDPs, as required, at 
clinic visits per the Schedule of Activities ( Appendix 2 ). They will receive insulated bags with 
cooling gel packs for use in transporting the SDP carton from the site to home. Investigational 
products in each participating country will be labeled according to the country’s regulatory 
requirements.  
Where appropriate, SGLT2 inhibitors and metformin may be obtained locally by [CONTACT_81109]. It is 
acceptable for patients to continue obtaining metformin by [CONTACT_81110]. In the 
case of individual countries, with study team approval, it is acceptable for patients to continue 
obtaining SGLT2 inhibitors by [CONTACT_81111]. In the [LOCATION_002] and Puerto 
Rico, a prescription card will be ava ilable for patients to obtain these medications, with a 
prescription.  
Clinical trial materials in each participating country will be labeled according to the country’s 
regulatory requirements.  
Dulaglutide demonstration pens will be provided for subcutaneou s injection training at the site; 
these pens do not have needles and do not contain study drug.  
Patients will also be provided with a commercially available PG meter and test strips to use 
during the study. Sufficient study drug material and glucose testin g supplies will be dispensed, 
as needed, at each visit.  
Study site staff must regularly assess w hether the patient is correctly administering the assigned 
study drug and storing the study drug according to the provided instructions.  
H9X-MC-GBGE(a) Clinical Protocol  Page 28 
LY2189265   
  
6.6. Dose  Modification  
No adjustment in injectable study drug dose (dulaglutide or placebo) will be allowed.  
During the 24 -week treatment period, participants are required to continue using their 
concomitant OAMs. Discontinuation of these medications or changes in th eir dose is not 
permitted, except in situations where dose adjustments or complete discontinuation is requir ed 
per country -specific label or when allowed per study protocol, for example, in the case of 
hypoglycemic epi[INVESTIGATOR_1841] (Section [IP_ADDRESS] ). 
 
6.6.1.  Special Treatment  Considerations  
[IP_ADDRESS].  Standards of Medical  Care  
Maintenance of adequate glycemic control in study participants may be enhanced but should not 
be compromised due to trial participation. Investigators and other study team members are 
expected to treat patients according to the nationally established stand ards of care for diabetes 
management in respective participating countries, except where that treatment would be in 
conflict with the protocol -provided treatment requirements.  If there are no local standards of 
care for diabetes, the investigators should follow current published standards of care from the 
American Diabetes Association and the European Association for Study of Diabetes (Inzucchi et 
al. 2015) during their patients’ participation in this study.  
This section provides guidance on management of epi[INVESTIGATOR_81064], 
persistent hyperglycemia. For effective implementation of measures described here, it is 
important that patients, and their caregivers, if applicable, be well -educated about the signs and 
symptoms of hyperglycemi a (eg, severe thirst, dry mouth, frequent micturition, or dry skin) and 
hypoglycemia (eg, intense hunger, sweating, tremor, restlessness, irritability, depression, 
headaches, disturbed sleep, or transient neurological disorders). Patients should be instruc ted to 
contact [CONTACT_81112], persistent hyperglycemia or severe 
hypoglycemia between study visits.  
[IP_ADDRESS].  Management of Increased Hypoglycemia  Risk  
If a hypoglycemic event occurs, the patient should record in the study diary the P G level 
measured during the epi[INVESTIGATOR_81065] (if taken), as well as 
associated symptoms, and treatment administered. Site personnel should educate and encourage 
patients to measure and record PG values during the symptoms of  hypoglycemia and enter the 
results into their study diaries. Patients should be instructed to call the investigative site as soon 
as possible if they experience a hypoglycemic event that requires assistance to administer 
treatment.  
Investigators should us e the following definitions and criteria when diagnosing and categorizing 
an epi[INVESTIGATOR_10920]: (the PG values in this section refer to 
values determined by a laboratory or International Federation of Clinical Chemistry and 
Laboratory Medicine plasma -equivalent glucose meters and strips) (American Diabetes 
Association 2005):  
H9X-MC-GBGE(a) Clinical Protocol  Page 29 
LY2189265   
  
 Documented symptomatic hypoglycemia is defined as any time a patient feels that 
he/she  is experiencing  symptoms  and/or  signs  associated  with hypoglycemia,  and has 
a PG level of ≤70 mg/dL (≤3.9  mmol/L).  
 Asymptomatic hypoglycemia is defined as any event not accompanied by [CONTACT_11017][INVESTIGATOR_81066] a measured PG of ≤70 mg/dL (≤3.9  mmol/L).  
 Probable symptomatic hypoglycemia is defined as an event during which 
symptoms of hypoglycemia are not accompanied by a PG determination (but that  was 
presumably caused by a PG concentration of ≤70 mg/dL [≤3.9  mmol/L]).  
 Severe  hypoglycemia  is defined  as an epi[INVESTIGATOR_81067], glucagon, or other resuscitative actions. 
These epi[INVESTIGATOR_81068]. Plasma glucose measurements may not be available during such an event,  
but neurological recovery attributable to the restoration of PG to normal is considered 
sufficient evidence that the event was induced by a low PG concentration.  
 Nocturnal  hypoglycemia  is defined  as any hypoglycemic  event  that occurs  between  
bedtime and w aking.  
Cases of relative hypoglycemia, defined as symptomatic events during which the person reports 
any of the typi[INVESTIGATOR_81069], 
but a measured PG concentration of >70 mg/dL (>3.9 mmol/L),  will also be collected.  
If a hypoglycemic event meets the criteria of severe, it needs to be recorded as serious on the AE 
case report form (CRF) and reported to Lilly as an SAE.  
In each case of suspected or confirmed hypoglycemia, it is important that th e event be properly 
categorized, the effect of the intervention be assessed, and the frequency of hypoglycemia be 
evaluated. The role of dietary changes and physical exercise (or any other contributing factor) in 
the development of an event should be estab lished. The patient should receive additional 
education, if deemed appropriate.  
Because of its mechanism of action, no adjustment of dulaglutide dose should be made to 
counteract increased risk of hypoglycemia. If, in the opi[INVESTIGATOR_871], treat ment 
regimen requires adjustment because of repeated epi[INVESTIGATOR_17221], initial step should 
be dose reduction of metformin, followed by [CONTACT_81113], if needed. In the case of 
continuously increased risk of hypoglycemia despi[INVESTIGATOR_81070], dose 
reduction or complete withdrawal of the SGLT2 inhibitor is permitted.  
Investigators are responsible for their patients’ management and well -being; therefore, it is their 
responsibility to implement these generally recommended inter ventions provided above, taking 
into account clinical and other relevant criteria.  
[IP_ADDRESS].  Management of Patients with Severe, Persistent Hyperglycemia  during 
the Treatment  Period  
An additional therapeutic intervention should be considered in patients who develop persistent , 
severe hyperglycemia after randomization based on the following criteria:  
H9X-MC-GBGE(a) Clinical Protocol  Page 30 
LY2189265   
  
 
a) Average daily PG from the 4 -point SMPG profile >240 mg/dL over at le ast a [ADDRESS_88368] 4 weeks  postrandomization;  or 
b) Average daily PG >200 mg/dL over a [ADDRESS_88369] an acute condition causing severe hyperglycemia. The 
investigator will decide in consultation with the patient on an appropriate glucose -lowering 
intervention (rescue) after considering relevant cl inical criteria. Other GLP -[ADDRESS_88370] not be 
included in the rescue intervention.  Patients who receive a new intervention should also 
continue administering study drug for the remaining period in the trial.  
 
6.7. Treatment  Compliance  
The assessment of treatmen t compliance with study drug (dulaglutide or placebo) will be 
determined by [CONTACT_716]:  
 Information about the administration of once weekly study drug injections will be entered 
into the patient diary by [CONTACT_81114]; 
this information will be collected in the  eCRF;  
 Study drug accountability will be checked at every visit. For that purpose, patients  will 
be instructed to return the study drug carton at the next study visit. They will also be 
instructed to return any unused study drug at the next study visit;  
 In both treatment arms, treatment compliance for once weekly study drug for each visit 
interval is defined as taking at least 75% of the required doses of study drug as assessed 
by [CONTACT_8786]; this information will be entered in the  eCRF.  
Other aspects of compliance with the study treatments will also be assessed at each visit based on 
the patient’s  adherence to the visit schedule, compliance with the concomitant SGLT2 inhibitor 
and metformin and requirements for non -study glucose -lowering agents, completion of study 
diaries, results of SMPG, and any other parameters the investigator considers necess ary. Patients 
considered to be poorly compliant with their  medication and/or the study procedures (for 
example, missed visits or specific diagnostic tests) will receive additional training and 
instructions, as required in the protocol.  
 
6.8. Concomitant  Therap y 
Patients  are permitted  to use concomitant  medications  that they require  during  the study,  except 
certain medications that may interfere with the assessment of efficacy and safety characteristics 
of the study  drug.  
Investigative site staff will inform pat ients that they must consult with the investigator or a 
designated site staff member upon being prescribed any new medications during the study, 
except when initiated for treatment of medical emergencies. Any additional medication initiated 
during the cour se of the study (including OTC drugs, such as paracetamol or aspi[INVESTIGATOR_248]) must be 
documented, and the name [CONTACT_81155](s) of administration must be recorded in the 
patient’s diary and on the “Concomitant Medications” section of the eCRF. In additi on, for  
H9X-MC-GBGE(a) Clinical Protocol  Page 31 
LY2189265   
  
 
allowed concomitant glucose -lowering agents, the dosage will also be documented and collected 
(SGLT2 inhibitors and metformin).  
Nonstudy medications taken by [CONTACT_81115] l not be 
reported to Lil ly unless an SAE or AE occurs that the investigator believes may have been 
caused by a study procedure.  
6.8.1.  Antihyperglycemia  Medications  
The only glucose -lowering agents that are allowed 3 -months prior to study entry and during the 
study are study drug and concomitant SGLT2 inhibitors and metformin. In addition, short -term 
insulin use for management of medical emergencies is allowed prior t o study entry and after 
randomization (Visit 5), but not during screening and lead -in/stabilization (Sections 5.1 and 5.2). 
Rescue therapy with other glucose -lowering agents, including insulin, may be medically 
indicated in certain situations after randomization. These situations are described in Section  
[IP_ADDRESS]  (severe, persistent hyperglycemia) and in Section 7.1.1  (early discontinua tion of study 
drug). If any such situation occurs, the patient may be treated with any locally -approved 
glucose -lowering agent, except other GLP -[ADDRESS_88371] be differentiated from short -term use of insulin t herapy for medical emergencies when 
reported in the eCRF.  
Patients who receive any glucose -lowering agents 3 months prior to entry or during the  screening 
or lead -in/stabilization periods, other than those allowed, will not be eligible for further 
particip ation in the trial. The patients not using metformin prior to study entry (Visit 1) are not 
allowed to initiate this therapy between study entry and Visit 5 . Patients who violate this 
requirement will be considered as ineligible and will be discontinued f rom further participation 
in this  trial. 
If any new glucose -lowering medication is initiated after randomization at Visit 5, other than 
rescue therapy or short -term use of insulin for medical emergencies, the patient will be required 
to immediately discont inue the medication and the appropriate study deviation report will be 
generated. Any such violation of the protocol that lasted longer than 14 days will exclude the 
patient from the Per Protocol (PP) population. Patients who receive insulin therapy for 
management of medical emergencies >14 days as well as those who receive rescue therapy, will 
also be excluded from the PP population.  
[IP_ADDRESS].  Allowed Concomitant  OAMs  
The key requirements for use of SGLT2 inhibitors and metformin, the allowed OAMs in 
Study GBGE, are  provided in Section 5.1 and Section 5.2.  Table GBGE.3  provides minimum  
required and maximum approved doses for these agents (Note: for SGLT2 inhibitors, these ar e 
the only approved doses per country -specific labels [“low” and “high” dose]; therefore, no other 
doses should be used during this study). The minimum required doses correspond to the lowest 
recommended dose per country -specific label and may not be the s ame dose in all participating 
countries. All prescribed doses to the study participants must comply with country -specific 
labels for these medications.  
H9X-MC-GBGE(a) Clinical Protocol  Page 32 
LY2189265   
  
 
Table  GBGE.3.  Required Doses of Concomitant SGLT2 Inhibitors and  Metformin  in 
Study GBGE for Patients Already Using These  Agents  
 
Drug Class  Minimum -Required Dose a Maximum Dose a 
Canagliflozin  
eGFR >60 mL/min/1.73 m 2  
100 mg QD   
300 mg QD  
eGFR 45 -60 mL/min/1.73 m 2 100 mg QD  100 mg QD  
eGFR <45 mL/min/1.73 m 2 Contraindicated  Contraindicated  
Dapagliflozin    
eGFR ≥60 mL/min/1.73 m 2 5 or 10 mg QD b 10 mg QD  
eGFR <60 mL/min/1.73 m 2 Contraindicated  Contraindicated  
Empagliflozin    
eGFR >60 mL/min/1.73 m 2 10 mg QD  25 mg QD  
eGFR 45 -60 mL/min/1.73 m 2 10 mg QD  10 or 25 mg QD b 
eGFR <45 mL/min/1.73 m 2 Contraindicated  Contraindicated  
Metformin    
eGFR ≥60 mL/min/1.73 m 2 1500 mg c 2550 mg or 3000 mg b 
eGFR <60 mL/min/1.73 m 2 Contraindicated  Contraindicated  
Abbreviations: eGFR = estimated glomerular filtration rate; QD = once -daily; SGLT2 = sodium -glucose co - 
transporter 2.  
a Based on the labels approved in participating  countries.  
b These  doses  may differ  in different  countries,  and country -specific  labels  are required  to be followed  to reach 
decisions appropriate for individual  patients.  
c Lower dose allowed in the case of documented  intolerability.  
Note: eGFR calculated by [CONTACT_81105] -Epi[INVESTIGATOR_623] (CKD -EPI) equation and will be provided by 
[CONTACT_27671].  
 
 
[IP_ADDRESS].1.  SGLT2  Inhibitors  
Patients in this study are required to be treated with an SGLT2 inhibitor for at least [ADDRESS_88372] the minimum required dose, per 
country -specific label. The dose may be adjusted between Visit 2 and  Visit 3, if required per 
label and to comply with the protocol requirements. Dose adjustment may be considered in the 
following situations:  
a) For patients who are on the minimum -required doses of SGLT2 inhibitors that is lower 
than the maximum approved dose  at study entry (Visit 1); no further dose increase for 
these  patients  is required;  however,  if judged  by [CONTACT_81116],  dose increase  is not prohibited;  
b) For patients with a confirmed eGFR 45 to 59 mL/min/1.73 m2 (see Appendix 2  for 
further details on handling of low eGFR): dapagliflozin, if used, should be immediately 
discontinued when required per label; for these patients,  they could either be discontinued 
from the study, or if the local label allows, patients could be prescribed another SGLT2 
inhibitor to maintain eligibility; the dose of canagliflozin and empagliflozin, if used, 
would need to be reduced if required per lo cal label (see Table  GBGE.3 ). 
For patients who adjust their SGLT2 inhibitor regimen between Visit 2 and Visit 3 for reasons 
described under a) and b), or for any other reason per product label, they will be required to  
H9X-MC-GBGE(a) Clinical Protocol  Page 33 
LY2189265   
  
 
undergo stabilization. The type and dose of SGLT2 inhibitor should remain unchanged during 
stabilization. For all randomized patients, the type and dose of the SGLT2 inhibitor should 
remain unchanged during the treatment period other than as described belo w. 
Those patients who discontinue therapy with SGLT2 inhibitors prior to randomization at Visit 5 
will be discontinued from the trial.  
After randomization, dose adjustment or discontinuation of SGLT2 inhibitors is allowed under 
the following circumstances:  
 in situations that require short -term treatment interruption consistent with the product 
labeling for each respective  country;  
 in situations that require dose adjustment or discontinuation per country -specific  label,  
for example, in the case of reduced eGFR;  
 in the case of increased  hypoglycemia  risk during  the treatment  period  (as described  in 
Section  [IP_ADDRESS] ). 
Dose reduction/discontinuation of SGLT2 inhibitors during the trial should be  properly 
documented.  
In patients who require rescue therapy, dose increase of SGLT2 inhibitors is allowed, but the 
dose and the reason for change must be properly documented in the eCRF.  
[IP_ADDRESS].2.  Metformin  
Patients in this study are not required to be treated with  metformin to be eligible for 
participation, but if used for at least [ADDRESS_88373] 12 weeks prior to randomization at Visit 5. If 
metformin therapy adjustment is required at Visit 2 per label and/or to meet protocol dosing 
requir ements, the site personnel will instruct the patient on the changes needed prior to Visit 3. 
Metformin treatment adjustments may be considered in the following situations:  
a) If the dose of metformin is less than the minimum -required (≥1500 mg/day) at Visit 1 ; 
the dose should  be up-titrated  based  on efficacy  and safety  parameters  per label;  a lower 
dose will be acceptable only in the case of documented (ie, recorded in the patient’s 
medical file) poor GI tolerability of the minimum required dose (that is, the highest 
tolerated  dose)  prior  to Visit  1 or between  Visit  2 and Visit  3; 
b) For patients who are on the minimum -required doses of metformin that is lower than the 
maximum approved dose at study entry (Visit 1), no further dose increase is required; 
however, if judged by [CONTACT_81117], 
dose increase is not  prohibited;  
c) For patients with a confirmed eGFR 45  to 59 mL/min/1.73 m2 (see Appendix 2  for 
further details on the handling of low eGFR); metformin should be immediately 
discontinued when required per country -specific label (see Table  GBGE.3 ); 
H9X-MC-GBGE(a) Clinical Protocol  Page 34 
LY2189265   
  
 
For patients who change their metformin regimen between Visit 2 and Visit 3 for reasons 
described under a), b) and c), or for any other reason per product label, the patient will be 
required to undergo stabilization and the dose should remain unchanged dur ing stabilization. For 
all randomized patients, the dose of metformin should remain unchanged during the entire study 
other than as described below.  
Those patients who discontinue metformin between Visit 3 and Visit 5 will be discontinued from 
the trial. D iscontinuation of metformin, if required per label, is allowed prior to Visit 3, in which 
case, the patient will perform stabilization.  
Dose adjustment or discontinuation of metformin is allowed after randomization under the 
following circumstances:  
 in situations  that require  short -term treatment  interruption  in line with the product 
labeling for each respective  country;  
 in situations that require dose adjustment or discontinuation per country -specific label, 
for example, in the case of reduced  eGFR;  
 in the case of increased  hypoglycemia  risk during  the treatment  period  (as described  in 
Section  [IP_ADDRESS] ). 
Dose reduction/discontinuation of metformin during the trial should be properly documented.  
In patients who require rescue therapy, dose increase or initiation of metformin is allowed, but 
the dose and the reason for change/initiation must be properly documented in the eCRF.  
6.8.2.  Medications that Promote Weight  Loss  
Prescription or OTC medications tha t promote weight loss are exclusionary if used 3 months 
prior to study entry, or between study entry and randomization at Visit 5 (see Section 5.2). 
These medications are also not allowed at any time during the treatment peri od. If started, they 
should be immediately withdrawn. Patients who use any medication from these groups during 
the treatment period will not be included in the PP analysis if the duration of use is >14 days 
(cumulative). In addition, patients should not re ceive a diet/exercise program with the intent of 
reducing body weight at any time during the study, other than the lifestyle and dietary measures 
for diabetes treatment (see Section 5.4). 
 
6.8.3.  Systemic  Glucocorticoids  
Chronic sys temic glucocorticoid therapy (with the exception of topi[INVESTIGATOR_2855], intraocular, intra - 
articular, or intranasal preparations) is exclusionary if used >14 consecutive days during the 
1-month period before study entry or between study entry and randomization at V isit 5. This  
therapy is not allowed during the treatment period and patients who require >[ADDRESS_88374] of randomized therapi[INVESTIGATOR_81071]. If initiation of any new blood pressure  
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88375] be 
documented in the eCRF.  
6.9. Treatment after Study  Completion  
6.9.1.  Continued  Access  
After study treatment is discontinued, an appropriate diabetes treatment regimen will  be initiated 
by [CONTACT_093].  
H9X-MC-GBGE(a) Clinical Protocol  Page 36 
LY2189265   
  
7. Discontinuation  Criteria  
7.1. Discontinuation from Study  Treatment  
Study drug may be interrupted temporarily or discontinued permanently.  
 
7.1.1.  Permanent Discontinuation of Study  Treatment  
Patients will be permanently discontinued from study drug in the following circumstances:  
 For inadvertently  enrolled  patients  for whom  it was determined  that continued  treatment 
with study drug would not be medically appropriate (see Section  7.1.4 ); 
 Exclusion Criteria [31] and [38] develop(s), after randomization (see Section  5.2); 
 The patient  is diagnosed  by [CONTACT_81118];  
 A patient  is diagnosed  with C-cell hyperplasia  or medullary  thyroid  carcinoma  after 
randomization;  
 If a patient develops an eGFR <30 mL/min/1.73m 2 as calculated by  [CONTACT_9289] -EPI; 
 If the patient  or the patient’s  designee,  for example,  legal  guardian,  requests  to be 
withdrawn from study  drug;  
 If the investigator or sponsor decides that the patient should be withdrawn from study 
drug; if the sponsor decides to permanently discontinue study treatment because of an 
SAE or a clinically significant laboratory value, Lilly or its designee should be alerted 
immediately [see Section  8.2.1 ]); 
 Discontinuation of the investigational product for abnormal liver tests should be 
considered  by [CONTACT_81119]  a patient  meets  one of the following  condition s after 
consultation with the Lilly designated medical  monitor:  
o ALT  or aspartate  aminotransferase  (AST)  >8X upper  limit  of normal  (ULN)  
o ALT or AST >5X ULN for more than [ADDRESS_88376]  >3X ULN  and total bilirubin  level  (TBL)  >2X ULN  or prothrombin 
time >1.5X  ULN  
o ALT  or AST  >3X ULN  with the appearance  of fatigue,  nausea,  vomiting,  right 
upper -quadrant  pain or tenderness,  fever,  rash,  and/or  eosinophilia  (>5%)  
o Alkaline phosphatase (ALP) >3X  ULN  
o ALP >2.5X ULN and TBL >2X  ULN  
o ALP >2.[ADDRESS_88377] wi th the appearance of fatigue, nausea, vomiting, right upper - 
quadrant pain or tenderness, fever, rash, and/or eosinophilia  (>5%)  
Those patients who stop the study drug permanently will receive another glucose -lowering 
intervention (rescue) and will continu e participation in the trial according to the protocol, to 
collect all planned efficacy and safety measurements. The rescue intervention must not include 
another GLP -1 RA.  
H9X-MC-GBGE(a) Clinical Protocol  Page 37 
LY2189265   
  
7.1.2.  Permanent Discontinuation from the  Study  
Every attempt should be made to keep patients in the trial irrespective of their adherence to 
treatment with study drug in order to minimize the amount of missing data and to enable 
assessment of study objectives as planned by [CONTACT_4690]. Patient d iscontinuation from 
the study early may be warranted in the following situations for ethical or legal reasons:  
 Exclusion Criterion  [11] 
 When a female patient becomes  pregnant;  
 When a patient is enrolled in another clinical trial involving an investigational product or 
is enrolled in any other type of medical research judged not to be scientifically or 
medically compatible with this  study.  
Patients may also discontinue from the study due to:  
 Spons or or Investigator  Decision  
o If Lilly or its designee stops the study or if Lilly or the investigator stops the 
patient’s  participation  in the study  for medical,  safety,  regulatory,  or other  reasons 
consistent  with applicable  laws,  regulations,  and good  clinical  practice  (GCP)  
 Patient  Decision  
o The patient or the patient’s designee, for example, legal guardian, requests to  be 
withdrawn from the  study  
Prior to early study discontinuation, the patient will discontinue study drug and will have end -of- 
study procedures (ET visit) performed as shown in the Schedule of Activities ( Appendix 2 ). 
During the ET visit the patient will be prescribed an appropriate glucose -lowering regimen and 
glucose self -monitoring plan.  
 
7.1.3.  Temporary Int erruption of Study  Treatment  
In certain situations after randomization, the investigator may need to temporarily discontinue 
(interrupt) study drug (for example, due to an AE or a clinically significant laboratory value). If 
study drug interruption is due to an AE, the event is to be documented and followed according to 
the procedures in Section 8.[ADDRESS_88378]. An inadvertently enrolled patient may be allowed to continue treatment  
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88379] patients who fail to return for a scheduled visit or were otherwise 
unable to be followed up by [CONTACT_81120]. 
H9X-MC-GBGE(a) Clinical Protocol  Page 39 
LY2189265   
  
8. Study Assessments and Procedures  
Appendix 2  lists the Schedule of Activities, with the study procedures and their timing (including 
tolerance limits for timing).  
Appendix [ADDRESS_88380] results. Certain samples may 
be retained for a longer period, if necessary, to comply with applicable laws, regulations, or 
laboratory certification standards (Sections 8.7 and 8.8). 
8.1. Efficacy  Assessments  
8.1.1.  Primary Efficacy  Assessments  
The primary efficacy measure is change in HbA1c from baseline at 24 weeks.  
 
8.1.2.  Secondary Efficacy  Assessments  
The following key secondary efficacy measures will be evaluated at 24 weeks:  
 Proportion of patients achieving HbA1c target of  <7.0%  
 Changes in FBG from baseline measured at the central  laboratory  
 Changes in body weight from  baseline  
Other secondary efficacy measures will also be evaluated at 24 weeks:  
 Proportion of patients achieving HbA1c target of  ≤6.5%  
 Changes from baseline in PG from 6 -point SMPG  profile  
 Changes in fasting glucagon from  baseline  
 
8.1.3.  Exploratory  Assessments  
The follow ing exploratory measures will be evaluated at 24 weeks:  
 Percentage  of patients  achieving  HbA1c  target  <7.0%,  with no weight  gain and no 
documented symptomatic  hypoglycemia  
 Percentage of patients achieving HbA1c target <7.0%, with body weight loss >5%, and 
no documented symptomatic  hypoglycemia  
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88381].  
After the informed consent form (ICF) is signed, study site personnel will record via eCRF the 
occurrence and nature of each patient’s preexisting conditions, including clinically significant 
signs and symptoms of the disease under tr eatment in the study. In addition, site personnel will 
record via eCRF any change in the condition(s) and any new conditions as AEs . Investigators 
should record their assessment of the potential relatedness of each AE to study procedure, 
investigational p roduct, and study device via eCRF.  
The investigator decides whether he or she interprets the observed AEs as reasonably possibly 
related to disease, to the investigational product, study device, study procedure, or other 
concomitant treatment or pathologie s. To assess the relationship of the AEs, the following is 
defined:  
Reasonably Possibly Related : Reasonable possibility that there is a cause and effect 
relationship between the investigational product, study device, and/or study  procedure 
and the  AE. 
The investigator answers yes/no when making this assessment.  
Planned surgeries and nonsurgical interventions should not be reported as AEs unless the 
underlying medical condition has worsened during the course of the study.  
If a patient’s investigational product is discontinued as a result of an AE, study site personnel 
must report this to Lilly or its designee via eCRF, clarifying if possible, the circumstances 
leading to any dosage modifications, or discontinuations of trea tment.  
H9X-MC-GBGE(a) Clinical Protocol  Page 41 
LY2189265   
  
8.2.1.  Serious Adverse  Events  
An SAE is any AE from this study that results in one of the following outcomes:  
 death  
 initial  or prolonged  inpatient  hospi[INVESTIGATOR_059]  
 a life -threatening experience (that is, immediate risk of  dying)  
 persistent or significant  disability/incapacity  
 congenital anomaly/birth  defect  
 considered significant by [CONTACT_81121]: important medical 
events that may not result in death, be life -threatening, or require hospi[INVESTIGATOR_81072],  based  upon  appropriate  medical  judgment.  
Although all AEs after signing the ICF are recorded in the eCRF, SAE reporting begins after the 
patient has signed the ICF and has received investigational product. However, if an SAE occurs 
after signing the ICF, but prior to receiving investigational product, it needs to be reported 
ONLY if it is considered reasonably possibly related to study procedure.  
Study site personnel must alert Lilly or its designee of any SAE within 24 hours of investigator 
awareness of the event via a sponsor -approved method. If alerts are issued via telephone, they 
are to be immediately followed with official notification on stu dy-specific SAE forms. This 
24-hour notification requirement refers to the initial SAE information and all follow -up SAE 
information.  
Pregnancy (during maternal or paternal exposure to investigational product) does not meet the 
definition of an AE. Howeve r, to fulfill regulatory requirements any pregnancy should be 
reported following the SAE process to collect data on the outcome for both mother and fetus.  
Investigators are not obligated to actively seek AEs or SAEs in subjects once they have 
discontinued and/or completed the study (the patient summary CRF has been completed). 
However, if the investigator learns of any SAE, including a death, at any time after a subject has 
been discharged from the study, and he/she considers the event reasonably possibly r elated to the 
study treatment or study participation, the investigator must promptly notify Lilly.  
Requirements for the reporting of severe hypoglycemia epi[INVESTIGATOR_1841], AEs of pancreatitis, and AEs 
of systemic hypersensitivity as SAEs are found in Section 8.2.2.  
[IP_ADDRESS].  Suspected Unexpected Serious Adverse  Reactions  
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator identifies as related to investigational product or procedure. 
[LOCATION_002] 21 CFR 312.32 and European Union Clinical Trial Directive 2001/20/EC and the 
associated detailed guidances or national regulatory requirements in participating countries 
require the reporting of S[LOCATION_003]Rs.  Lilly has procedures that will be followed for the recording 
and expedited reporting of S[LOCATION_003]Rs that are consistent with global regulations and the associated 
detailed guidances.  
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88382]  
[IP_ADDRESS].  Hypoglycemia and  Hyperglycemia  
Patients will collect information on epi[INVESTIGATOR_81073] [ADDRESS_88383] study 
visit ( Visit 11 or ET visit).  For that purpose, patients will be trained about signs and symptoms 
of hypoglycemia, how to treat hypoglycemia, and how to collect appropriate information for 
each epi[INVESTIGATOR_81074] (see Section [IP_ADDRESS] ) according to the Schedule 
of Activities ( Appendix 2 ). Site personnel will enter this information into the eCRF at each visit 
after Visit.  
Events of interest related to hyperglycemia (rescue therap y for severe, persistent hyperglycemia, 
per criteria specified in Section [IP_ADDRESS],  and ketoacidosis) will be collected during the trial to 
assess the risk of extreme disbalance in glycemic control.  
[IP_ADDRESS].  Pancreatitis  
Acute pancreatitis is defined as an AE of interest in all trials with dulaglutide, including this trial. 
Acute pancreatitis is an acute inflammatory process of the pancreas that may also involve 
peripancreatic tissues and/or remote organ systems (Banks and  Freeman 2006). The diagnosis of 
acute pancreatitis requires 2 of the following 3 features:  
1. Abdominal pain, characteristic of acute pancreatitis (generally located in the 
epi[INVESTIGATOR_81075] [Banks and 
Freem an 2006; Koizumi et al. 2006]; the pain is often associated with nausea  and 
vomiting);  
2. Serum amylase (total and/or pancreatic) and/or lipase ≥3×ULN;  or 
3. Characteristic  findings  of acute  pancreatitis  on computed  tomography  (CT)  scan 
or magnetic resonance ima ging (MRI).  
If acute pancreatitis is suspected, appropriate laboratory tests (including levels of pancreatic 
amylase and lipase) should be obtained via the central laboratory (and locally, if needed).  
Imaging studies, such as abdominal CT scan with or without contrast, MRI, or gallbladder 
ultrasound, should be performed. If laboratory values and/or abdominal imaging supports the 
diagnosis of acute pancreatitis, the patient must discontinue therapy with investigational product 
but will continue in the study on another glucose -lowering regimen (see Section 6.8.1  and 
Section 7.1.1  for details on rescue intervention). The most appropriate diabetes  therapeutic 
regimen will be decided by [CONTACT_093], based on the patient’s clinical status. A review of 
the patient’s concomitant medications should be conducted to assess any potential causal 
relationship with pancreatitis .  
Each case of AE of pancr eatitis must be reported.  If typi[INVESTIGATOR_10926]/or symptoms of 
pancreatitis are present and confirmed by [CONTACT_11018] (lipase or amylase [total and/or 
pancreatic]) and imaging studies, the event must be reported as an SAE.  For a potential case that  
H9X-MC-GBGE(a) Clinical Protocol  Page 43 
LY2189265   
  
does not meet all of these criteria, it is up to the investigator to determine the seriousness of the 
case (AE or SAE) and the relatedness of the event to study drug.  
In addition to the diagnostic assessment in patients who develop symptoms of acute pancreatitis, 
each patient will have measurements of pancreatic amylase and lipase at screening, baseline, and 
the last study visit (Visit  11 [Week 24] or ET visit), to ass ess any potential effects of dulaglutide 
on the exocrine pancreas (refer to the Schedule of Activities, Appendix 2 ). Further diagnostic 
assessment per Lilly algorithm for assessment of asymptomatic pancreatic hyperenzymemia will 
be required whenever lipase and/or pancreatic amylase are ≥3×ULN at any time during the study. 
If this situation occurs at Visit 11 (Week 24), the patient will be required to undergo this 
additional work -up, and the data will be collected in the clini cal trial database.  
All AEs of acute or chronic pancreatitis, as well as cases of confirmed lipase or pancreatic 
amylase values ≥3×ULN, will be adjudicated by [CONTACT_81122]. 
In addition, AEs of severe or serious abdominal pa in of unknown etiology will also be submitted 
to the adjudication committee to assess for possible pancreatitis or other pancreatic dis ease.  
Relevant data from patients with acute or chronic pancreatitis, those with severe or serious 
abdominal pain, and t hose that undergo additional assessments due to confirmed 
hyperenzymemia will be entered into a specifically designed eCRF page by [CONTACT_81123]. The adjudication committee representative will enter the results of adjudication in a 
correspondin g eCRF page.  
[IP_ADDRESS].  C-Cell Hyperplasia and C -Cell Neoplasms  
Individuals with personal or family history of certain thyroid or nonthyroid endo crine 
abnormalities or certain preexisting laboratory and genetic characteristics will be excluded from 
the study (see Se ction 5.2).  The assessment of thyroid safety during the trial will include 
reporting of thyroid treatment -emergent adverse events (TEAEs) and measurements of calcitonin 
according to the Schedule of Activities ( Appendix 2 ) at screening, baseline, and Visit 11  
(Week 24). The purpose of calcitonin measurements is to assess the potential of dulaglutide 
versus placebo to affect the thyroid C -cell function, which may indicate development of C -cell 
hyperplasia and neoplasms.  
Patients who develop serum calcitonin increases ≥50% of the mean of the baseline and screening 
values AND an absolute value ≥20 pg/mL and <35 pg/mL at Visit 11 (Week 24) will be asked to 
repeat the measurement within 1 month. If th is repeat value is increasing (≥10% increase), the 
patient will be recommended that he or she undergo additional endocrine assessment and longer - 
term follow -up by [CONTACT_81124] a serious adverse effect on the gland.  
Patients with an increa se in serum calcitonin ≥50% of the mean of the baseline and screening 
values AND an absolute value ≥35 pg/mL at Visit 11 (Week 24) will be recommended to 
immediately undergo additional endocrine assessments and longer term follow -up by [CONTACT_81125].  
H9X-MC-GBGE(a) Clinical Protocol  Page 44 
LY2189265   
  
 
For patients who require additional endocrine assessment because of increased calcitonin 
concentration per criteria provided in this section, data from the follow -up assessment will be 
collected in the specific section of the eCRF.  
[IP_ADDRESS].  Cardio vascular  Events  
Deaths and nonfatal CV AEs will be adjudicated by a committee of physicians external to Lilly 
with cardiology expertise. The nonfatal CV AEs to be adjudicated include: MI; hospi[INVESTIGATOR_81076]; hospi[INVESTIGATOR_19934]; coronary int erventions (such as coronary 
artery by[CONTACT_81126]); and cerebrovascular events, including 
cerebrovascular accident (stroke) and transient ischemic attack (TIA).  
[IP_ADDRESS].  Renal  Events  
Renal safety will be assessed based on repeat ed renal functional assessment, as well as 
assessment of AEs suggestive of acute and chronic renal failure.  
[IP_ADDRESS].  Allergic/Hypersensitivity  Reactions  
All allergic or hypersensitivity reactions will be reported by [CONTACT_81127], if 
any serious  criterion is met, as SAEs. Additional data, such as type of reaction and treatment 
received, will be collected on any AEs or SAEs that the investigator deems related to study drug 
via a CRF created for this purpose. Study drug should be temporarily interr upted in any 
individual suspected of having a severe or serious allergic reaction to study drug (Section 7.1.3 ). 
Study drug may be restarted when/if it is safe to do so, in the opi[INVESTIGATOR_871]. If study 
drug is pe rmanently discontinued, the patient will receive another glucose -lowering treatment, 
judged by [CONTACT_81128]’s clinical status, and will 
continue in the trial to collect all planed efficacy and safety measurements (see Section 6.8.1  and 
Section 7.1.1 ). 
 
8.2.3.  Complaint  Handling  
Lilly collects product complaints on investigational products and drug delivery systems used in 
clinical studies in order to ensure the safety of study participants, monitor quality, and to 
facilitate process and product improvements.  
Patients will be inst ructed to contact [CONTACT_81129] a 
complaint or problem with the investigational product so that the situation can be assessed.  
 
8.3. Treatment of  Overdose  
Study drug overdose will be reported as an AE. In the event of ove rdose, refer to the IB and/or 
Product Label.  
 
8.4. Safety  Assessments  
8.4.1.  Electrocardiograms  
Epi[INVESTIGATOR_81077]2 
inhibitors, while treatment with dulaglutide increases the mean heart rate (HR) (2 to 4 beats/min) 
and the mean duration of the PR interval (2 to 3 msec). To assess the e ffect of their combined  
H9X-MC-GBGE(a) Clinical Protocol  Page 45 
LY2189265   
  
 
use on cardiac electrophysiology in Study GBGE , electrocardiograms (ECGs) will be collected 
according to the Schedule of Activities ( Appendix 2 ) and centrally overread. Electrocardio grams 
should be recorded according to the study -specific recommendations included in the Manual of 
Operations for the study, using standardized equipment provided by [CONTACT_1034].  
Each ECG tracing will be assessed by [CONTACT_81130]. Any clinically significant findings from ECGs that result in a diagnosis 
and that occur after the patient receives the first dose of the investigational treatment should be 
reported to Lilly or its designee as an AE vi a eCRF. Results of the central overread will be 
entered into the clinical trial database and will be used for the statistical analysis of the effects of 
the randomized treatments. In addition, once the overread ECG is returned from the centralized 
ECG vend or, the investigator, or qualified designee, is responsible for determining if any change 
to the patient management is needed. The investigator, or qualified designee, must document 
his/her review of the ECG printed at the time of evaluation, the final ove rread ECG report issued 
by [CONTACT_81131], and any alert reports.  
 
8.4.2.  Blood Pressure and Heart  Rate  
Sitting blood pressure (BP) and HR will be measured according to the Schedule of Activities 
(Appendix 2 ), using sta ndardized equipment provided by [CONTACT_1034]. Vital sign measurements 
should be taken before obtaining an ECG tracing, at visits where required (see Schedule of 
Activities, Appendix 2 ), and before collection of blood samples for laboratory testing. For each 
parameter, 2 measurements will be taken using the same arm. An appropriately sized cuff (cuff 
bladder encircling at least 80% of the arm) should be used to ensure the accuracy of BP 
measurements. The arm used for the BP mea surement should be supported at heart level. Each 
measurement of sitting HR and BP is to be recorded in the eCRF. Any AE related to changes in 
BP and HR should be reported, per requirements provided in Section 8.2. 
8.4.3.  Laboratory  Tests  
For each patient, laboratory tests detailed in Appendix 3  should be conducted according to the 
Schedule of Activities ( Appendix 2 ). 
Any clinically significant findings from laboratory tests that result in a diagnosis and that occur 
after the patient receives the first dose of investigational product should be reported to Lilly or its 
designee as an AE via eCRF.  
 
8.4.4.  Body Weight and Body Ma ss Index  
Body weight will be measured at prespecified time points (see Schedule of Activities,  Appendix  
2). Each patient’s weight should be measured according to a standardized protocol ( Appendix 7 ). 
Body mass index will be computed from the patient’s weight and height.  
 
8.4.5.  Safety  Monitoring  
Lilly will periodically review evolving aggregate safety data within the study by [CONTACT_81132], including trends in s afety variables, laboratory analytes, and AEs. Lilly will also 
review SAEs within time frames mandated by [CONTACT_10984]. The Lilly study physician  
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88384].  
In addition, specific safety measures are included in the protocol to ensure appropriate 
monitoring of pancreatic, thyroid, and liver safety. Laboratory findings that trigger pancreatic 
and thyroid safety mo nitoring per Lilly standards are provided in Section [IP_ADDRESS]  and [IP_ADDRESS].  
Details of the liver safety monitoring are provided in Appendix 4.  If a study patient ex periences 
elevated ALT ≥3X ULN, ALP ≥2X ULN, or elevated TBL ≥2X ULN, clinical and laboratory 
monitoring should be initiated by [CONTACT_093]. Details for hepatic monitoring depend upon 
the severity and persistence of observed laboratory test abnormalit ies. To ensure patient/subject 
safety and comply with regulatory guidance, the investigator is to consult with the Lilly CRP 
regarding collection of specific recommended clinical information a nd follow -up laboratory 
tests.  
 
8.5. Pharmacokinetics  
Not applicable.  
 
8.6. Pharmacodynamics  
Not applicable.  
 
8.7. Genetics  
A blood sample will be collected for pharmacogenetic analysis where local regulations and 
ERBs allow ( Appendix 2 ). These samples are not being collected to create a biobank for 
conducting unspecified disease or population genetic research either now or in the future. 
Samples may be used to investigate variable response to dulaglutide, and to investigate genetic 
varia nts thought to play a role in diabetes and diabetes -related complications. Assessment of 
variable response may include evaluation of AEs or differences in efficacy. These studies may 
include  but are not limited  to the genetic  variants  in drug target  pathwa y (glucagon -like peptide  1 
receptor [GLP1R]) genes and genes associated with diabetes and related complications (eg, 
transcription factor 7-like 2 [TCF7L2]).  Samples will be retained for a maximum of [ADDRESS_88385] visit, or as local regu lations and ERBs allow, for the study at a facility 
selected by [CONTACT_456]. This retention period enables use of new technologies, response to 
regulatory questions, and investigation of variable response that may not be observed until later 
in drug develo pment or when the drug is commercially available. Molecular technologies are 
expected to improve during the 15 year storage period and therefore cannot be specifically 
named.  However, existing approaches include whole genome or exome sequencing, genome 
wide association studies, candidate gene studies, a nd epi[INVESTIGATOR_81078]. Regardless of the 
technology utilized, genotypi[INVESTIGATOR_81079].  
8.8. Biomarkers  
Serum and plasma samples for non -genetic  biomarker research will be collected at the times 
specified in the Schedule of Activities ( Appendix 2 ) where local regulations and ERBs allow.  
H9X-MC-GBGE(a) Clinical Protocol  Page 47 
LY2189265   
  
 
Samples will be used for research on the drug target, disease p rocess, pathways associated with 
T2D, mechanism of action of dulaglutide, and/or research method or in validating diagnostic 
tools or assay(s) related to T2D.  
All biomarker samples will be coded with the patient number. These samples and any data 
generated can be linked back to the patient only by [CONTACT_10991]. Samples will 
be destroyed according to a process consistent with local regulations.  
Samples will be retained for a maximum [ADDRESS_88386] patient visit for the study, or for a 
shorter period if local regulations and ERBs impose shorter time limits, at a facility selected by 
[CONTACT_456]. This retention period enables use of new te chnologies, response to regu latory 
questions, and investigation of variable response that may not be observed until later in drug 
development or when the drug is commercially available.  
8.9. Health  Economics  
Not applicable.  
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88387] 90% probability of achieving 
statistical significance for either dulaglutide 1.[ADDRESS_88388] deviation (SD) of 1.2%, a difference 
between dulaglutide and placebo of 0.6%, and a 2 -sided significance level of 0.025. Assuming 
that the dropout rate is 15% for the entire study period, the study will need to enroll  at least  
119 patients in each arm for a total of 357 patients enrolled. Assuming a screen fail rate of 40%, 
a total of 595 patients will be screened to meet these enrollment number requirements.  
9.2. General Statistical  Considerations  
Statistical analysis of t his study will be the responsibility of Eli Lilly and Company or its 
designee. Any change to the data analysis methods described in the protocol will require an 
amendment ONLY if it changes a principal feature of the protocol. Any other change to the data 
analysis methods described in the protocol, and the justification for making the change, will be 
described in the statistical analysis plan (SAP) or the clinical study report (CSR). Additional 
exploratory analyses of the data will be conducted as deemed ap propriate.  
The primary analysis population will be the intent -to-treat (ITT) population, defined as all 
patients randomized who have received at least [ADDRESS_88389] number of measurements (HbA1c, percent to goal in H bA1c, FBG, and body weight) will 
also be evaluated in the PP population. The PP population will be based on patients who were 
compliant with study medication, took no concomitant medications that would confound the 
interpretation of results (such as system ic steroids or non -study glucose -lowering agents used  
>14 days), and have an HbA1c measurement at the primary visit endpoint.  
Analyses of certain efficacy outcomes (HbA1c, percent to goal in HbA1c, FBG, body weight) 
and hypoglycemia will be performed on the full dataset with censoring as primary (ie, to exclude 
data collected after initiation of rescue with glucose -lowering thera py for reasons described in 
Section [IP_ADDRESS],  Section 6.8.1,  and Section 7.1.1 ). These same analyses will also be performed 
without censoring post rescue data as se nsitivity analyses.  
Unless otherwise noted, all tests of treatment effects will be conducted at a 2 -sided alpha level of 
0.05, and confidence intervals (CIs) will be calculated at 95%, [ADDRESS_88390] nonmissing measurement taken 
prior to Visit 5 will be used for the baseline measurement. For HbA1c, if baseline data are 
missing, the imputation will be conducted only if an additional value betwee n Visit 2 and 
randomization (patients not needing stabilization) or Visit 4 and randomization (patients needing 
stabilization) is collected. The endpoint for the primary analysis is defined as the change from 
baseline in HbA1c at 24 weeks (Visit 11). Key s econdary endpoints are percent to goal in  
H9X-MC-GBGE(a) Clinical Protocol  Page 49 
LY2189265   
  
 
HbA1c (<7.0%) at 24 weeks and change from baseline in FBG (central laboratory) and body 
weight at 24 weeks.  
Two analysis models will be used for the primary and key secondary continuous efficacy 
measures. The primary analysis will be mixed -model repeated measure (MMRM) analysis using 
restricted maximum likelihood (REML) (Section 9.4.1). An unstructured covariance structure 
will be used to model the within -patient errors. If this model fails to converge, the following 
covariance structures will be tested in order:  
 Toeplitz with  heterogeneity  
 autoregressive with heterogeneity, by  [CONTACT_765] 
 compound symmetry with heterogeneous variances by  [CONTACT_765],  
 Toeplitz,  autoregressive  
 compound  symmetry  without  heterogeneous  variances,  by [CONTACT_81133].  
The secondary analysis for the primary and key secondary continuous endpoints will be analysis 
of covariance (ANCOVA) (Section 9.4.2 ). Missing endpoints will be imputed with the last 
(postbaseline) observation carried forward  (LOCF). The percentage of patients achieving the 
target HbA1c of <7.0% at 24 weeks will be analyzed using a longitudinal logistic regression with 
repeated measurements (Section 9.4.2 ). 
A graphical testing approach will be used to strongly control for type [ADDRESS_88391] for 
superiority of each of the dulaglutide doses versus placebo at 24 weeks for the following 
measures: (1) change from baseline in HbA1c, (2) change from baseline in FB G (central 
laboratory), (3) percent achieving HbA1c <7.0%, and (4) change from baseline in body weight.  
For continuous measures, summary statistics will include sample size, mean, SD, median, 
minimum, and maximum for both the actual and change from baselin e measurements. Least - 
squares mean (LS mean) and standard errors derived from the model will also be displayed for 
the change from baseline measurements. Treatment comparisons will be displayed showing the 
treatment difference LS mean and the 95% CIs for the treatment differences (dulaglutide – 
placebo), along with the p -values for the treatment comparisons.  
For categorical measures, summary statistics will include sample size, frequency, and 
percentages. Fisher’s exact test will be used for treatment comp arisons, unless 80% of cells have 
an expected value of at least 5, in which case the chi -square test will be used.  
9.3. Treatment Group  Comparability  
9.3.1.  Patient  Disposition  
A detailed description of patient disposition will be provided at the end of the study.  
Frequency counts and percentages of all patients entered, randomized/enrolled, completing, 
discontinuing from the study drug early, and discontinuing from the study early will be presented 
for each of the treatment groups. The reasons for discontinuation from  the study and/or study  
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88392].  
 
9.3.2.  Patient  Characteristics  
Demographic and baseline characteristics will be summarized for both treatment arms.  
 
9.3.3.  Concomitant  Therapy  
Glucose lo wering agents will be summarized by [CONTACT_81134], baseline (Visit 5), and for the 
entire 24 -week treatment period. Doses of SGLT2 inhibitors and metformin will be summarized 
at baseline (Visit 5). Other prespecified concomitant medications of interes t will be summarized 
by [CONTACT_81135] (Visit 5). Frequency of use of non -study glucose -lowering medications 
will be summarized at baseline (Visit 5) and for the entire [ADDRESS_88393] 75% of required 
injections. Overall compliance is defined as being at least 75% compliant with study drug for at 
least 75% of the visits. The investigator will advise the patient that injections should be given at 
approximately the same time of the day, on the same day of the week. Compliance will be 
summarized by [CONTACT_81136], by [CONTACT_81137]. Listings will also be produced.  
9.4. Primary and Secondary  Analyses  
9.4.1.  Primary Outcome Measure and  Analyses  
The primary outcome is an efficacy estimand defined as the difference in HbA1c mean change 
from baseline to [ADDRESS_88394] -rescue data censored (excluded). The 
primary hypothesis of interest in this placebo -controlled stu dy is whether dulaglutide has 
superior  efficacy  compared  to placebo,  in patients  already  treated  with SGLT2  inhibitors,  without  
confounding with rescue  therapy.  
The primary analysis model will be an MMRM for HbA1c change from baseline to 24 weeks in 
the IT T population (Visit 11) with treatment, country, SGLT2 inhibitor dose (“low” vs. “high”; 
see Section 6.2), metformin use (“yes” vs. “no”), visit and treatment -by-visit as fixed effects, 
baseline HbA1c as a covariate, and pati ent as a random effect.  
[IP_ADDRESS].  Additional Analyses of the Primary  Outcome  
The primary analysis model, MMRM, will be repeated using the PP population to check the 
sensitivity of the analys is.  If the conclusion differs from that of the ITT population, the data and  
analyses will be further investigated. The secondary analysis model will be an ANCOVA for 
HbA1c change from baseline to 24 weeks (Visit 11), using a similar model as described above 
with treatment, country, SGLT2 inhibitor dose (“low” versus “high”), and metformin use (“yes”  
H9X-MC-GBGE(a) Clinical Protocol  Page 51 
LY2189265   
  
 
versus “no”) as factors and baseline HbA1c as a covariate. Missing endpoints will be imputed 
with the LOCF using postbaseline data only.  
To investigate departure from the Missing At Random (MAR) assumption for the primary 
analysis that excludes post -rescue data, a sensitivity analysis using a particular missing not at 
random (MNAR) assumption will be performed. Specifically, a placebo multi ple imputation 
(pMI) will be performed (Ayele et al. 2014), which assumes that the drug effect in missing data 
and post -rescue data in both the placebo arm and dulaglutide arm was like the observed effect in 
the placebo arm (excluding post -rescue data). Th is is essentially the “copy reference” approach 
as described in Carpenter et al. 2013. This approach is in essence assuming that the drug effect 
will decay over time, in accordance with the correlation structure implied by [CONTACT_26739]. Data 
imputed this way w ill be analyzed with the same MMRM model as the primary analysis. This 
particular MNAR assumption can be viewed as a “worst reasonable case” assess ment of the 
efficacy estimand, or as an effectiveness estimand that assumes patients with missing data or 
rescued patients received no drug benefit after dropout or rescue.  
Also of interest is the effectiveness/treatment regimen estimand that evaluates the difference in 
mean HbA1c change from baseline to 24 weeks in the ITT population regardless of treatment 
discontinuation or use of rescue therapy (ITT estimand). Therefore as a supportive analysis, 
MMRM will be performed on the ITT population with all post -rescue data up to the primary 
endpoint of 24 weeks included.  
For both the efficacy estimand (missing data a nd post -rescue data both considered as missing), 
and the ITT estimand (post -rescue data not treated as missing), a tippi[INVESTIGATOR_81080] a MAR assumption. However, prior to 
analysis, in the dula glutide arm the imputed values will be replaced by [CONTACT_81138]. Multiple values of delta will be tried until the value at which the conclusion from the 
MMRM analysis changes.  
9.4.2.  Secondary Outcome Measures and  Analyses  
The key secondary continuous efficacy measures will also be analyzed using both models, the 
MMRM and the ANCOVA with LOCF models described above (with and without censoring 
data collected after initiation of rescue intervention). Analysis of other secondar y efficacy 
measures that are continuous variables, except glucagon (for glucagon, see Section 9.5.6 ), will be 
performed using MMRM on the ITT population. There will be no multiplicity adjustment for 
pairwise comparisons.  Th e MMRM and ANCOVA models will include the model terms given 
for the previously described primary analysis model with the addition of the HbA1c strata 
(≤8.0%,  >8.0%).  
For percentages of patients achieving target HbA1c of <7.0% (including exploratory composi te 
endpoints with body weight and hypoglycemia) or ≤6.5% at [ADDRESS_88395] -rescue data excluded (considered missing), and separately 
with all post -rescue data included. In addition, an analysis of percentage of patients on HbA1c  
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88396] -baseline data 
being considered (imputed) as not having achieved the target.  
9.5. Safety  Analyses  
The safety analysis will include measurements of AEs, SAEs, hypoglycemic and hyperglycemic 
epi[INVESTIGATOR_1841], and laborat ory analytes. Unless otherwise specified, the ITT population will be used 
for analyses of safety measures.  
9.5.1.  Study Drug  Exposure  
Exposure to each study treatment will be calculated for each patient and summarized by 
[CONTACT_1570]. The time points for expos ure summaries will be defined in the SAP.  
9.5.2.  Adverse  Events  
Adverse events will be coded from the actual term using the Medical Dictionary for Regulatory 
Activities (MedDRA) and reported in preferred term and system organ class (SOC). Selected 
notable AEs of interest may be reported using high -level terms. All AEs and TEAEs, defined as 
postbaseline events that are new events or preexisting conditions that worsened in severity after 
randomization, will be listed by [CONTACT_69867].  Information on treatment, actual term, 
preferred term, severity, seriousness, and r elationship to study drug will also be reported.  
Summary statistics will be provided of TEAEs, SAEs, and study discontinuation due to AEs or 
death during the treatment period. Counts and proportions of patients experiencing AEs will be 
reported for each tr eatment group, and chi -square tests will be used to compare the treatment 
groups.  
Listings of patients experiencing allergic and hypersensitivity reactions, as well as those 
discontinuing the study due to AEs, will be produced.  
 
9.5.3.  Hypoglycemic  Epi[INVESTIGATOR_81081] [IP_ADDRESS]  contains definitions of categories of hypoglycemia. A listing of individual 
hypoglycemic epi[INVESTIGATOR_81082]. Summary reports will include both 
incidence and rates of hypoglycemia for the ITT  population (with post -rescue data censored, and 
without post -rescue data censored). Hypoglycemia will be categorized as “documented 
symptomatic,” “asymptomatic,” “probable,” “severe,” or “nocturnal,” and for all events 
combined, “total hypoglycemia.” Only  “documented symptomatic” and “total hypoglycemia” 
will be analyzed inferentially.  
Baseline hypoglycemia risk will be established based on hypoglycemia events recorded  between 
Visit 2 and Visit 5. The incidence of hypoglycemic epi[INVESTIGATOR_81083] b y frequencies 
and percentages for each treatment group, by [CONTACT_81139]. Treatment differences in 
the incidence of hypoglycemic epi[INVESTIGATOR_81084] a logistic regression. Treatment 
differences in rates of hypoglycemic epi[INVESTIGATOR_1841] (epis odes/patient/30 days; epi[INVESTIGATOR_1841]/patient/year) 
will be assessed by [CONTACT_81140] -based model for repeated measures. The model will include 
the same terms as in the primary analysis model with baseline hypoglycemia as a  covariate  
H9X-MC-GBGE(a) Clinical Protocol  Page 53 
LY2189265   
  
 
instead of baseline HbA1c. The logarithm of days between visit s will be adjusted as an offset to 
account for possible unequal duration between visits and between patients. Certain categories of 
hypoglycemia may also be evaluated using a PG cutoff <54 mg/dL (<3.0 mmo l/L). 
9.5.4.  Hyperglycemic  Epi[INVESTIGATOR_81085] (if appropriate) will be provided for events of severe, persistent 
hyperglycemia resulting in initiation of rescue therapy, as well as events of ketoacidosis.  
9.5.5.  Special Safety  Topi[INVESTIGATOR_1102]  
[IP_ADDRESS].  Pancreas  Safety  
Listings and summaries of adjudicated pancreatic events will be provided.  
[IP_ADDRESS].  Cardiovascular  Safety  
Listings and summaries of adjudicated CV events will be provided. Heart rate and systolic and 
diastolic blood pressure from vital signs will be summarized as well as ECG data. Adverse 
events suggestive of hypotension will be provided.  
[IP_ADDRESS].  Thyroid  Safety  
Listin gs of AEs of interest associated with the thyroid gland (benign and malignant neoplasms) 
will be produced, as well as a listing of biopsy reports.  
[IP_ADDRESS].  Renal  Safety  
To assess renal safety, summary and analyses will be provided for eGFR, as well as shift tables.  
Listing of AEs suggestive of acute and chronic kidney failure will also be provided. Other 
reports may also be generated if deemed appropriate.  
[IP_ADDRESS].  Allergic/Hypersensitivity  Reactions  
Summaries and listings of allergic and other hypersensitivity AEs will be p rovided.  
 
9.5.6.  Laboratory  Analytes  
Laboratory measurements will be listed by [CONTACT_69867]. An additional listing will be 
presented for laboratory measurements that are outside the normal range.  
Laboratory measurements will also be summarized. For continuous (numeric) laboratory 
analytes, including glucagon, the change from baseline to endpoint will be analyzed using an 
analysis of variance (ANOVA) on the rank -transformed data, with treatment as f ixed effects. 
Last observation carried forward will be used to impute missing postbaseline values.  
For subjective (qualitative) laboratory analytes, counts and percentages of patients with normal 
and abnormal values will be analyzed using chi -square tests.  
 
9.6. Pharmacokinetic/Pharmacodynamic  Analyses  
Not applicable.  
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88397] interaction  visit - 
by-treatment -by- [subgroup]. The [ADDRESS_88398] interaction of treatment -by-[subgroup] at the primary 
time point of [ADDRESS_88399] with the 
subgroup levels. S ignificance will be evaluated at alpha=0.10. The following are candidate 
subgroups that might be analyzed.  This list is not necessarily  all-inclusive:  
 baseline age group (<65 years, ≥65 years)  
 race 
 ethnicity  
 country  
 duration of diabetes at baseline (<median duration and ≥median  duration)  
 BMI (<median and  ≥median)  
 concomitant  metformin  
 baseline HbA1c (≤8.0%,  >8.0%)  
 baseline glucagon (<median and  ≥median)  
When analyzing baseline HbA1c as a subgroup, the baseline HbA1c will not be included as a 
covariate to avoid confounding.  
A subgroup analysis will also be performed for the change from baseline in body weight by 
[CONTACT_81141], using a similar appr oach as described for HbA1c above. Other 
subgroups may be assessed when considered appropriate.  
For all subgroup analyses, if the MMRM fails to converge, then the corresponding ANCOVA 
model (LOCF) will be used.  
 
9.8. Interim  Analyses  
No interim analyses ar e planned for this study. If an unplanned interim analysis is deemed 
necessary, the appropriate Lilly medical director, or designee, will be consulted to determine 
whether it is necessary to amend the protocol.  
H9X-MC-GBGE(a) Clinical Protocol  Page 55 
LY2189265   
  
10. Study Governance  Considerations  
10.1.  Regulatory and Ethical Considerations, Including the Informed 
Consent  Process  
10.1.1.  Informed  Consent  
The investigator is responsible for ensuring:  
 that the patient  understands  the potential  risks  and benefits  of participating  in 
the study  
 that informed consent is given by [CONTACT_57996]. This 
includes obtaining the appropriate signatures and dates on the ICF prior to  the 
performance of any protocol procedures and prior to the administration of 
investigational  product.  
 answering any questions the patient may have throughout the study and 
sharing in a timely manner any new information that may be relevant to the 
patient’s  willingness  to continue  his or her participation  in the trial. 
 
10.1.2.  Ethical  Review  
The investigator must give assurance that the ERB was properly constituted and convened as 
required by [CONTACT_81142] (ICH) guidelines and other applicable 
laws and regulations.  
Documentation of ERB approval of the protocol and the ICF must be provided to Lilly before the 
study may begin at the investigative site(s). Lilly or its representatives must approve the ICF, 
including any changes made by [CONTACT_41429], before it is used at the  investigative site(s). All ICFs 
must be compliant with the ICH guideline on GCP.  
The study site’s ERB(s) should be provided with the following:  
 the current IB or package labeling  and updates during the course of the  study  
 ICF 
 relevant curricula  vitae  
 study  diary  
10.1.3.  Regulatory  Considerations  
This study will be conducted in accordance with:  
 consensus  ethics  principles  derived  from  international  ethics  guidelines,  including 
the Declaration of Helsinki and Council for International Organizations of 
Medical Sc iences (CIOMS) International Ethical  Guidelines  
 applicable ICH GCP  Guidelines  
 applicable laws and  regulations  
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88400] -party organization (TPO).  
 
10.1.4.  Investigator  Information  
Physicians with a specialty in diabetes/endocrinology internal medicine, family medicine, or 
general medicine with clinical research experience will participate as investigators in this clinical 
trial. 
 
10.1.5.  Protocol  Signatures  
The sponsor’s responsible medical  officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of  the 
study.  
After reading the protocol, each principal investigator [INVESTIGATOR_81086] e page and 
send a copy of the signed page to a Lilly representative.  
10.1.6.  Final Report  Signature  
[CONTACT_81156] [INVESTIGATOR_81087], indicating agreement 
that, to the best of his or her knowledge, the report accurately desc ribes the conduct and  results 
of the  study.  
The sponsor’s responsible medical officer and statistician will approve the final CSR for this 
study, confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study.  
 
10.2.  Data Quality  Assurance  
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the following:  
 provide  instructional  material  to the study  sites,  as appropriate  
 sponsor start -up training to instruct the investigators and study coordinators. This 
training will give instruction on the protocol, the completion of the CRFs, and 
study  procedures.  
 make periodic visits to the study  site 
 be available for consultation and stay in contact [CONTACT_81143], telephone, and/or  fax 
 review and evaluate CRF data and use standard computer edits to detect errors  in 
data collection  
 conduct a quality review of the  database  
In addi tion, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study site. The study may be audited by [CONTACT_81144], and/or regulatory agencies at any time. Investigators wil l be given notice before 
an audit occurs.  
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88401] data or ECG data, will be stored electronically in the 
central vendor’s database system. Data will subsequently be t ransferred from the central vendor 
to the Lilly generic labs system.  
Any data for which paper documentation provided by [CONTACT_81145]’s study file. Paper 
documentat ion provided by [CONTACT_81146], for example, a paper diary to collect patient - 
reported outcome measures (for example, a rating scale), a daily dosing schedule, or an event 
diary.  
Data from complaint forms submitted to Lilly will be encoded and s tored in the global product 
complaint management system.  
10.3.  Study and Site  Closure  
10.3.1.  Discontinuation of Study  Sites  
Study site participation may be discontinued if Lilly, the investigator, or the ERB of the study 
site judges it necessary for medical, safety, re gulatory, or other reasons consistent with 
applicable laws, regulations, and GCP.  
 
10.3.2.  Discontinuation of the  Study  
The study will be discontinued if Lilly judges it necessary for medical, safety, regulatory, or 
other reasons consistent with applicable laws, regulations, and GCP.  
H9X-MC-GBGE(a) Clinical Protocol  Page 58 
LY2189265   
  
11. References  
American Diabetes Association. Defining and reporting hypoglycem ia in diabetes: a report from 
the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care . 
2005;28(5):1245 -1249.  
Ayele BT, Lipkovich I, Molenberghs G, Mallinckrodt CH. A multiple -imputation -based 
approach to sensitivity analyses and effectiv eness assessment s in longitudinal clinical trials. J 
Biopharm Stat . 2014;24(2):211 -228. 
Banks PA, Freeman ML; Practice Parameters Committee of the American College of 
Gastroenterology. Practice guidelines in acute pancreatitis. Am J Gastroenterol . 
2006;10 1(10):[ADDRESS_88402] on insulin secretion 
in healthy subjects. Diabetes Obes Metab . 2011;13(5):434 -438. 
Blonde L, Jendle J, Gross J, Woo V, Jiang H, Fahrbach JL, Milicevic Z. Once -weekly 
dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, 
in patients with type 2 diabetes (AWARD -4): a randomised, open -label, phas e 3, non - 
inferiority study. Lancet . 2015;385(9982):[ADDRESS_88403] procedures. Stat Med . 2009;28(4):586 -604. 
By[CONTACT_28556] [US package insert (USPI)]. Wilmington, DE: [COMPANY_008] Pharmaceuticals LP; 2015. 
Available at: http://www.azpi[INVESTIGATOR_24309].com/by[CONTACT_28556]/pi_by[CONTACT_28556].pdf#page=1.  Access ed July 
14, 2015.  
By[CONTACT_28557] [US package insert (USPI)]. Wilmington, DE: [COMPANY_008] Pharmaceuticals LP; 2015. 
Available at: http://www.azpi[INVESTIGATOR_24309].com/by[CONTACT_28557]/pi_by[CONTACT_28557].pdf#page=[ADDRESS_88404] MG. Analysis of longitudinal trials with protocol deviation: a 
framework for relevant, accessible assumptions, and inference via multiple imputation. J 
Biopharm Stat . 2013;23(6):1352 -1371.  
[DCCT] Th e Diabetes Control and Complications Trial Research Group. The effect of intensive 
treatment of diabetes on the development and progression of long -term complications in 
insulin -dependent diabetes mellitus. N Engl J Med .1993;329(14):[ADDRESS_88405] T, Gonzalez JG, Atisso C, Sealls W, Fahrbach JL. Once - 
weekly dulaglutide versus once -daily liraglutide in metformin -treated patients with type 2 
diabetes (AWARD -6): a randomised, open -label, phase 3, non -inferiority trial. Lancet . 
2014;384 (9951):1349 -1357.  
Farxiga  [US package  insert  (USPI)].  Wilmington,  DE: [COMPANY_008]  Pharmaceuticals  LP; 2015. 
Available at: http://www.azpi[INVESTIGATOR_24309].com/farxiga/pi_farxiga.pdf#page=1.  Accessed July 14, 
2015.  
H9X-MC-GBGE(a) Clinical Protocol  Page 59 
LY2189265   
  
Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V. Efficacy and safety of once 
weekly dulaglutide vs. insulin glargine in combination with metformin a nd glimepi[INVESTIGATOR_81088] 
2 diabetes patients (AWARD -2). Can J Diabetes . 2014;38(5):S4.  
Invokana [US package insert (USPI)]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2015.  
Available at:  http://www.invokana.com/prescribing -information.pdf.  Accessed July 14, 2015.  
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas 
A, Wender R, Matthews  DR. Management of hyperglycemia in type 2 diabetes, 2015: a 
patient -centred  approach.  Update  to a position  statement  of the American  Diabetes  Association 
and the European Association for the Study of Diabetes. Diabetologia . 2015;58(3):429 -442. 
Jardiance [ US package insert (USPI)]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, 
Inc.; 2014. Available at:  
http://bidocs.boehringer -ingelheim.com/ BIWebAccess/ViewServlet.ser?docBase=renetnt&fol  
derPath=/Prescribing+Information/PIs/Jardiance/jardiance.pdf. Accessed July14, 2015.  
Koizumi M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M, 
Kimura Y, [COMPANY_005] K, Isaji S, Otsuki M , Matsuno S; JPN. JPN Guidelines for the management 
of acute pancreatitis: diagnostic criteria for acute pancreatitis. J Hepatobiliary Pancreat Surg . 
2006;13(1):25 -32. 
Nauck M, Weinstock RS, Umpi[INVESTIGATOR_81089], Guerci B, Skrivanek Z, Milicevic Z. Efficacy and 
safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized 
controlled trial (AWARD -5). [erratum in Diabetes Care 2015 Mar;38(3):538]. Diabetes Care . 
2014;37(8):2149 -2158.  
Tanzeum [US package insert (USPI)]. Wilmington, DE: Gla xoSmithKline LLC; 2015. Available 
at: 
https://www.gsksource.com/pharma/content /dam /GlaxoSmi thKline/US/en/Prescribing_Inform  
ation/Tanzeum/pdf/TANZEUM -PI-MG-IFU-COMBINED.PDF. Accessed July 14, 2015.  
Trulicity [summary of product characteristics (SPC)]. Houten, The Netherlands; 2014. Available 
at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_ - 
_Product_Informati on/human/002825/WC500179470.pdf. Accessed July 14, 2015.  
Trulicity [US package insert (USPI)]. Indianapolis, IN: Eli Lilly and Company; 2015 . Available 
at:  http://pi.lilly.com/us/trulicity -uspi.pdf. Accessed July 14, 2015.  
[[LOCATION_006]PDS] [LOCATION_006] Prospective Diabetes Study Group. Intensive blood -glucose control with 
sulphonylureas or insulin compared with conventional treatment and risk of complications in 
patients with type 2 diabetes ([LOCATION_006]PDS 33). Lancet . 1998;352(9131):[ADDRESS_88406], Manghi FP, Shurzinske L, Pechtner V. Efficacy and safety of 
dulaglutide monotherapy vs metformin in type 2 diabetes in a randomized controlled trial 
(AWARD -3). Diabetes Care . 2014; 37(8):2168 -2176.  
Victoza [US package insert (USPI)]. Bagsvaerd, Denmark: Novo Nordisk A/S; 2015. Available 
at:  http://www.novo -pi.com/victoza.pdf.  Accessed July 14, 2015.  
H9X-MC-GBGE(a) Clinical Protocol  Page 60 
LY2189265   
  
Wysham C, Blevins T, Arakaki R,  Colon P, Atisso C, Kuhstoss D, Lakshmanan M. Efficacy and 
safety of dulaglutide added on to pi[INVESTIGATOR_81090] 2 
diabetes in a randomized controlled trial (AWARD -1). [erratum in Diabetes Care [ADDRESS_88407];37(10):2895]. Diabet es Care. 2014;37:2159 -2167.  
H9X-MC-GBGE(a) Clinical Protocol  Page 61 
LY2189265   
  
 
 
Appendix  1. Abbreviations and  Definitions  
 
 
 
 
Term  Definition  
 
AE adverse event:  Any untoward medical occurrence in a patient or  clinical  investigation  
subject administered a pharmaceutical product that does not necessarily have a causal 
relationship with this treatment. An adverse  event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigationa l) product.  
ALP alkaline  phosphatase  
ALT alanine  aminotransferase  
ANCOVA  analysis of  covariance  
ANOVA  analysis of  variance  
AST aspartate  aminotransferase  
blinding/masking  A double -blind study is one in which neither the patient nor any of the  investigator  or 
sponsor staff who are involved in the treatment or clinical evaluation of the patients are 
aware of the treatment  received.  
BMI body mass  index  
BP blood  pressure  
CIOMS  Council for International Organizations of Medical  Sciences  
complaint  A complaint is any written, electronic, or oral communication that  alleges  deficiencies  
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery  system.  
CI confidence  interval  
CRF/eCRF  case repo rt form/electronic case report  form  
CRP  clinical research physician:  Individual responsible for the medical conduct of the  study.  
Responsibilities of the CRP may be performed by a physician, clinical research 
scientist, global safety physician or other medical officer.  
CSR  clinical study  report  
CT computed  tomography  
CV cardiovascular  
ECG  electrocardiogram  
eGFR  estimated glomerular f iltration  rate 
enroll  The act of assigning a patient to a treatment.  Patients who are enrolled in the  trial are 
those who have been assigned to a  treatment.  
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88408]  
ET early  termination  
fasting  abstaining from food and drink (except water) for approximately 8  hours  (typi[INVESTIGATOR_897],  
overnight), no significant physical activity and no administration of glucose -lowering 
agents during this  period  
FBG  fasting blood  glucose  
GCP  good clinical  practice  
GI gastrointestinal  
GLP-[ADDRESS_88409]  
HbA1c  hemoglobin  A1c 
HR heart  rate 
IB Investigator’s  Brochure  
ICF informed consent  form  
ICH International Conference on  Harmonisation  
 
investigational 
product  A pharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial, including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marke ted products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.  
ITT intent to treat:  The principle that asserts that the effect of a treatment policy can  be best 
assessed by [CONTACT_41445] a patient (that is, the planned 
treatment regimen) rather than the actual treatment given. It has the consequence that 
patients allocated to a treatment group should be followed up, assessed, and analyzed as 
members of that group irrespective of their compliance to the planned course of 
treatment.  
IWRS  interactive web -response  system  
LOCF  last observation carried  forward  
LS mean  least-squares  mean  
MAR  missing at  random  
MedDRA  Medical Dictionary for Regulatory  Activities  
MEN  multiple endocrine  neoplasia  
MI myocardial  infarction  
MMRM  mixed -model repeated  measures  
H9X-MC-GBGE(a) Clinical Protocol  Page 63 
LY2189265   
  
 
 
MNAR  missing not at  random  
MRI magnetic resonance  imaging  
NAFLD  nonalcoholic fatty liver  disease  
OAM  oral antihyperglycemia  agent  
OTC  over the  counter  
PG plasma  glucose  
PP per protocol: The set of data generated by [CONTACT_81147], according to the underlying scientific  model.  
QD once  daily  
REML  restricted maximum  likelihood  
SAE serious adverse  event  
SAP statistical analysis  plan 
screen  The act of determining  if an individual  meets  minimum  requirements  to become  part of 
a pool of potential  candidates  for participation  in a clinical  study.  
SD standard  deviation  
SDP single -dose pen 
SGLT1/SGLT2  sodium -glucose co -transporter 1/sodium -glucose co -transporter  [ADDRESS_88410]  characteristics  
S[LOCATION_003]Rs  suspected unexpected serious adverse  reactions  
T2D type 2 diabetes  
TBL total bilirubin  level  
TEAE  treatment -emergent adverse event:  Any untoward medical occurrence that  either  occurs  
or worsens at any time after treatment baseline and that does not necessarily have to 
have a causal relationship with this  treatment.  
ULN upper limit of  normal  
USPI  [INVESTIGATOR_81091]  
H9X-MC-GBGE(a) Clinical Protocol  Page 64 
LY2189265   
  
 
 
Appendix  2. Schedule of  Activities  
 
H9X-MC-GBGE(a) Clinical Protocol  Page 65 
LY2189265   
  
 
Schedule of Activities, Protocol H9X -MC-GBGE  
Perform procedure as indicated.  
 
 Study 
Period I  Study Period II  Study Period III  
Screening  Lead in  Stabilization a Treatment Period  
Visit  1 2a 3 4 5b 6 7 8 9 10 11 ET 
Week of Treatment  -(2-14) -(1-13) -12 -1 0 2 4 8 12 18 24  
Allowable Deviation (Days)  ±3 ±3 ±3 ±3  ±3 ±3 ±7 ±7 ±7 ±7  
Informed consent  X            
Randomization c     X        
Clinical Assessments  
Medical History  X            
Physical  X          X X 
Height d X            
Weight d X    X X X X X X X X 
Electrocardiogram e X    X      X X 
Vital Signs (BP and HR 
measurements) f X    X X X X X X X X 
Preexisting conditions/adverse 
events  X X X X X X X X X X X X 
Concomitant medications  X X X X X X X X X X X X 
Review/record hypoglycemic 
events    X X X X X X X X X X 
Patient summary            X X 
H9X-MC-GBGE(a) Clinical Protocol  Page 66 
LY2189265   
  
 
Schedule of Activities, Protocol H9X -MC-GBGE  
 Study 
Period I  Study Period II  Study Period III  
Screen 
ing Lead 
in Stabilization a Treatment Period  
Visit  1 2a 3 4 5b 6 7 8 9 10 11 ET 
Week of Treatment  -(2-14) -(1-13) -12 -1 0 2 4 8 12 18 24  
Allowable Deviation (Days)  ±3 ±3 ±3 ±3  ±3 ±3 ±7 ±7 ±7 ±7  
Patient Education and Management  
Diet and exercise and SMPG trainings   X           
PG meter training   X           
Subcutaneous injection training   X  X         
Review of subcutaneous injection 
training      X        
Dispense PG meter/supplies g  X X X X X X X X X   
Dispense study diary, instruct in use   X X X X X X X X X   
Review/return study diary    X X X X X X X X X X 
Review/record 6 -point SMPG values h     X    X  X Xi 
Dispense study drug and/or injection 
supplies      X X X X X X   
Observe patient inject study drug      X        
Patient returns study drug and injection 
supplies       X X X X X X X 
Assess study drug compliance       X X X X X X X 
H9X-MC-GBGE(a) Clinical Protocol  Page 67 
LY2189265   
  
 
Schedule of Activities, Protocol H9X -MC-GBGE  
 Study 
Period I  Study Period II  Study Period III  
Screening  Lead in  Stabilization a Treatment period  
Visit  1 2a 3 4 5b 6 7 8 9 10 11 ET 
Week of Treatment  -(2-14) -(1-13) -12 -1 0 2 4 8 12 18 24  
Allowable Deviation (Days)  ±3 ±3 ±3 ±3  ±3 ±3 ±7 ±7 ±7 ±[ADDRESS_88411] k X    X        
Chemistry panel  X    X      X X 
Urinalysis panel      X      X X 
Urinary albumin/creatinine ratio      X      X X 
eGFR (CKD -EPI) l X    X      X X 
Calcitonin  X    X      X X 
Hematology  X    X      X X 
Lipid panel      X      X X 
HbA1c  X Xm  Xn   X  X  X X 
Pancreatic amylase, lipase  X    X      X X 
Fasting glucagon      X      X X 
Follicle -stimulating hormone test o X            
Stored Samples:              
Pharmacogenetic      X        
Nonpharmacogenetic      X  X  X  X X 
Abbreviations: BP = blood pressure; CKD -EPI = Chronic Kidney Disease -Epi[INVESTIGATOR_623]; CRF = case report form; CV = cardiovascular; eGFR = estimated 
glomerular filtration rate; ET = early termination; HbA1c = hemoglobin A1c; HR = heart rate; OAM = oral antihyp erglycemia medication; PG = plasma 
glucose; SMPG = self -monitored plasma glucose.  
a Visit 2:  Lead -in 
 Patients who require adjustment of their OAM regimen will implement treatment changes between Visits 2 and 3 (the lead -in period), all other patients 
will c ontinue with their prestudy regimen without  changes;  
 Patients who adjust their OAM regimen during lead -in and/or need to stabilize the regimen will perform Visit 3 (end of lead -in) as their next visit and 
will then run 1 to 12 -week stabilization. All other patients will skip Visit 3 and Visit 4 and will perf orm Visit 5 as their next  visit.  
b The final visit window is determined by [CONTACT_81148](s). The visit calculator should be used to determine the exact visit window for all 
subsequent  visits.  
c Baseline assessments must be completed before pr ocessing in the interactive web -response system  (IWRS).  
H9X-MC-GBGE(a) Clinical Protocol  Page 68 
LY2189265   
  
 
Schedule of Activities, Protocol H9X -MC-GBGE  
d Refer to Protocol Appendix 7  for standardized procedure.  
e     Refer to Protocol Section 8.4.1  for standardized procedure. 
f Refer to Protocol Section 8.4.2  for standardized  procedure.  
g    Dispense only as  needed.  
h One 6 -point SMPG profile should be performed by [CONTACT_81149] k prior to this  visit.  
i If performed prior to the  visit.  
j For Visits 5 and 11, and the ET Visit, patients should be reminded to report to the site in a fasting condition, after a peri od of approximately 8 hours without 
eating, drinking (except water), or any  significant physical activity and before taking their  OAMs.  
k A serum pregnancy test will be performed at Visit [ADDRESS_88412] injection of study drug for women of childbearing p otential only. Additional urine pregnancy tests may be 
performed at the investigator’s discretion during the  study.  
l The CKD -EPI [INVESTIGATOR_81092]. Values that are below important thresholds (60 mL/min/1.73 m 2 or 
45 mL/min/1.73 m 2) must be first confirmed at the next visit before any protocol -required treatment adjustment or other protocol -required action is 
implemented.  The higher of the 2 available  values should be used when making clinical decisions.  For example, if a patient’s eGFR value  is 
<45 mL/min/1.73 m 2 at Visit 1 but the value at Visit 2 is ≥45 mL/min/1.73 m 2, the patient will be allowed to continue in the trial.  
m HbA1c blood draw only for patients who do NOT require stabilization of the OAM  regimen.  
n HbA1c blood draw only for patients whose OAM regimen needs to be stabilized due to changes made between Visit 2 and Visit 3 and/or to meet requirements 
for stable doses of  OAMs.  
o  Follicle -stimulating hormone test performed at Visit [ADDRESS_88413] uterus, who has no t taken hormones 
or oral contraceptives within 1 year and has had  6 to 12 months of spontaneous amenorrhea.  
H9X-MC-GBGE(a) Clinical Protocol  Page 69 
LY2189265   
  
 
 
Appendix 3.  Clinical Laboratory  Tests  
 
H9X-MC-GBGE(a) Clinical Protocol  Page 70 
LY2189265   
  
 
Clinical Laboratory  Tests a  
Hematology  Clinical  Chemistry  
Hemoglobin  Sodium  
Hematocrit  Potassium  
Erythrocyte count  (RBC)  Total  bilirubin  
Mean cell  volume  (MCV)  Direct  bilirubin  
Mean cell hemoglobin  concentration  (MCHC)  Alkaline  phosphatase  
Leukocytes  (WBC)  Alanine aminotransaminase  (ALT/SGPT)  
Neutrophils  Aspartate aminotransaminase  (AST/SGOT)  
Lymphocytes  Gamma -glutamyl transferase  (GGT)  
Monocytes  Blood urea nitrogen  (BUN)  
Eosinophils  Creatinine  
Basophils  Creatine kinase (creatine phosphokinase;  CPK b) 
Platelets  Uric acid 
Calcium  
Urinalysis  Albumin  
Specific  gravity  Glucose  
pH 
Protein  Pancreas  (Exocrine) c 
Glucose  Serum pancreatic  amylase  
Ketones  Serum  lipase  
Bilirubin  
Urobilinogen  HbA1c  
Blood  
Nitrite  Pregnancy test serum and  urine d 
Leukocyte esterase  
 
Albumin/creatinine ratio (urine) e Follicle -stimulating hormone  
 
Lipid Panel  
Endocrine  Total  cholesterol  
Calcitonin c LDL f 
Fasting  glucagon  HDL  
VLDL  
Stored  Samples  Triglycerides  
Pharmacogenetic stored sample 
Biomarker stored sample  
 
Abbreviations: CK -MB = creatine kinase -MB; HbA1c = hemoglobin A1c; HDL = high -density lipoprotein 
cholesterol; LDL = low -density lipoprotein cholesterol; RBC = red blood cells; WBC = white blood cells; VLDL  
= very low de nsity lipoprotein cholesterol.  
a All tests will be performed  by a Lilly -designated  central  laboratory,  unless  otherwise  noted.  
b CK-MB is to be assayed if the creatine kinase result is >1000  IU/L.  
c Additional samples may be collected based on the investigator’s  judgment.  
d A serum screening pregnancy test will be performed at Visit [ADDRESS_88414] may be performed at the investigator’s discretion during the  study.  
e Urinary albumin and creatinine are measured; the ratio is  calculated.  
f This value will be calcul ated.  If triglycerides >400 ng/mL, then direct LDL will be  assayed.  
H9X-MC-GBGE(a) Clinical Protocol  Page 71 
LY2189265   
  
 
 
Appendix 4.  Hepatic Monitoring Tests for  Treatment - 
Emergent Abnormality  
 
 
 
 
Selected tests may be obtained in the event of a treatment -emergent hepatic abn ormality and may 
be required in follow -up with patients in consultation with the Lilly, or its designee, CRP.  
Hepatic Monitoring  Tests a  
Hematology b Haptoglobin b 
Hemoglobin  
Hematocrit  Hepatic  Coagulation b 
Erythrocyte count (RBC)  Prothrombin  Time  
Leukocytes  (WBC)  Prothrombin  Time,  INR 
Neutrophils,  segmented  
Lymphocytes  Hepatic  Serologies b 
Monocytes  Hepatitis A antibody,  total 
Eosinophils  Hepatitis A antibody,  IgM 
Basophils  Hepatitis B surface  antigen  
Platelets  Hepatitis B surface  antibody  
Hepatitis B Core an tibody  
Hepatic  Chemistry b Hepatitis  C antibody  
Total  bilirubin  Hepatitis E antibody,  IgG 
Direct  bilirubin  Hepatitis E  antibody,  IgM 
Alkaline  phosphatase  
Alanine  transaminase  (ALT/SGPT)  Anti -nuclear  antibody b 
Aspartate transaminase (AST/SGOT)  
Gamma -glutamyl  transferase  (GGT)  Alkaline Phosphatase  Isoenzymesb 
Creatine phosphokinase (CPK)  
Anti -smooth muscle antibody (or anti -actin 
antibody) b 
Abbreviations: IgG = immunoglobulin G; IgM = immunoglobulin M; INR = international normalised ratio (for 
blood clotting time); RBC = red blood cells; WBC = white blood cells.  
a Hepatic  safety  will be assessed  and monitored  throughout  the study,  based  on clinical  and laboratory  parameters.  
Any patient who develops abnormalities that meet standard criteria for hepatic assessment will be referred for 
clinical assessment in accordance with Lilly standards. Hepatic assessment may include the tests listed above , or 
others as clinically indicated, as part of patient follow -up, in consultation with Lilly -designated Medical Monitor.  
b Assayed by [CONTACT_11007] -designated or local  laboratory.  
H9X-MC-GBGE(a) Clinical Protocol  Page 72 
LY2189265   
  
 
 
Appendix 5.  Sampling  Summary  
 
 
 
 
This table summarizes the approximate number of samples (venipunctures) and volumes for all 
sampling (screening, standard laboratory, pharmacogenetic, biomarker, and exploratory) and 
tests during the study. Fewer samp les may actually be taken, but this will not require a protocol 
amendment.  
Protocol H9X -MC-GBGE Sampling Summary  
 
Purpose  Sample 
Type  Maximum Amount 
per Sample  Maximum 
Number Samples  Maximum 
Total Amount  
Screening testsa Blood  [ADDRESS_88415] laboratory testsa Blood  20 mL  6 120 mL  
Pharmacogenetic samples  Blood  10 mL  1 10 mL  
Other exploratory 
Nonpharmacogenetic samples  Blood  20 mL  4 80 mL  
Total Blood     220 mL  
Hepatic Monitoringb Blood  3-30 mL  - - 
a Additional samples may be drawn if needed for safety  purposes.  
b Based on laboratory safety values, unscheduled hepatic monitoring testing may be performed as part of patient 
follow -up, in consultation with Lilly -designated Medical  Monitor.  
H9X-MC-GBGE(a) Clinical Protocol  Page 73 
LY2189265   
  
 
 
Appendix 6.  Protocol GBGE World  Health  Organization  
Classification of Diabetes and Diagnostic  Criteria  
 
 
 
Type 1 Diabetes Mellitus (T1DM): Type 1 diabetes mellitus is judged to be present when the 
classical symptoms of diabetes (thirst, polyuria, wasting and stupor, or coma) are associated with 
readily detectable concentra tions of glucose and ketone bodies in the blood and urine. Insulin 
treatment is necessary not only to control hyperglycemia but also to prevent spontaneous ketosis 
and death.  
Type 2 Diabetes Mellitus (T2DM): Type 2 diabetes mellitus, although often asympto matic, 
may also present with classical hyperglycemic symptoms (thirst, polyuria, weight loss), but 
despi[INVESTIGATOR_81093], ketone bodies are present in only low concentrations in the blood and 
urine. Coma is rare in type 2 diabetes but may result from extre me hyperglycemia and 
hyperosmolarity; lactic acidosis or ketoacidosis can also occur in fulminating illness (for 
example, severe infection or mesenteric artery thrombosis) due to an acute increase in insulin 
requirements, but spontaneous ketosis does not o ccur. Some patients with type 2 diabetes later 
progress to a state of absolute insulin deficiency (Alberti and Zimmet 1998).  
H9X-MC-GBGE(a) Clinical Protocol  Page 74 
LY2189265   
  
 
 
Appendix 7.  Protocol GBGE World  Health  Organizat ion 
Standardized Protocols for the Measurement of  Height  
and Weight  
 
 
 
 
The following information has been adapted from standardized physical measurement protocols 
for the World Health Organization’s STEPwise approach to Surveillance (STEPS) (WHO 2008).  
Measuring Height  
Step 1   Ask the patient to remove their footwear and any headgear (light headgear worn 
for religious reasons can remain, but this should be worn by [CONTACT_81150]).  
Step [ADDRESS_88416]  (stadiometer)  or 
against a wall with their feet together and their knees straight with their heels 
against the back board or the stadiometer or the  wall.  
Step 3 Ask the patient to look straight ahead without tilting their he ad up. 
Step 4 Ask the patient to breathe in and stand tall.  If using a stadiometer  or fixed  
measuring device, move the device’s measurement arm gently down onto the top 
of the patient’s head.  Record the patient’s height in centimeters  (cm).  
Measuring Weight  
Body weight measurements should be done in a consistent manner using a calibrated scale 
(mechanical or digital scales are acceptable). All weights for a given patient should be measured 
using the same scale, whenever possible, after the pa tient has emptied their bladder. Patients 
should be lightly clothed but not wearing shoes while their weight is measured.  
Step 1    Ask the patient to remove their footwear and any headgear (light headgear worn 
for religious reasons can remain, but this sh ould be worn by [CONTACT_81151]).  
Step 2 Make sure the scale is placed on a firm, flat, even surface (not on carpet or on a  
slopi[INVESTIGATOR_81094] a rough uneven  surface).  
Step [ADDRESS_88417]  their 
weight in kilograms  (kg).  
H9X-MC-GBGE(a) Clinical Protocol  Page 75 
LY2189265   
  
 
 
Appendix 8. Protocol Amendment H9X-MC-GBGE(a) 
Summary – A Randomized, Parallel -Arm, Double -Blind 
Study of Efficacy and Safety of Dulaglutide When Added  
to SGLT2 Inhibitors in Patients with Type 2 Diabetes 
Mellitus  
 
 
 
Overview  
Protocol H9X -MC-GBGE, A Randomized, Parallel -Arm, Double -Blind Study of Efficacy and 
Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients with Type 2 Diabetes 
Mellitus has been amended. The new protocol is indicated by [CONTACT_61504] (a) and will be  used to 
conduct the study in place of any preceding version of the protocol.  
Based on regulatory guidance, changes were made to the protocol to include additional 
provisions to minimize the risk of early patient discontinuations from the study, and to con tinue 
to measure key endpoints at key time points in all randomized patients regardless of adherence to 
therapy or study protocol. This regulatory guidance also requested that additional statistical 
reports be included to provide data for incidence of earl y treatment discontinuation separate from 
the incidence of early study discontinuation and to assess the primary objective without and with 
data censored at the time point of rescue therapy initiation. The overall changes made to this 
protocol are as follo ws: 
 Added text in Section 1 stating that for the primary analysis, all available data up to 24 
weeks  will be included  except  those  collected  after initiation  of glucose -lowering  rescue 
therapy. The primary analysis will also be repeated with all available data  included.  
 Modified  text in Section  3 and Section  9.5.4  to state that patients  will initiate  rescue 
therapy for severe, persistent hyperglycemia, rather than  discontinue.  
 Added text in Section 4.[ADDRESS_88418] that patients developi[INVESTIGATOR_81095], severe 
hyperglycemia will continue administering study drug and receive a new glucose - 
lowering intervention (rescue). These patients, as well as those who receive rescue 
therapy after discontinuation of stu dy drug early, will remain in the study and will be 
asked to perform all study visits to collect planned efficacy and safety  measurements.  
 Added text in Section 4.3 describe that patients in the placebo arm with unacceptably 
high glycemia  during  the treatment  period  will be offered  additional  glucose -lowering 
intervention (rescue), rather than  discontinuation.  
 Added text in Section [IP_ADDRESS]  to instruct that for patients with severe, persistent 
hyperglycemia, the investigator will decide in consultation with the patient on an 
appropriate glucose -lowering intervention (rescue), and these patients should also 
continue administering study drug for the remaining period in the trial. Other GLP -[ADDRESS_88419]  not be included in the rescue  intervention.  
H9X-MC-GBGE(a) Clinical Protocol  Page 76 
LY2189265   
  
 Added text in Section 6.8.1  to advise that rescue therapy with other glucose lowering 
agents, including insulin, may be medically indicated in certain situations af ter 
randomization  (severe,  persistent  hyperglycemia;  early  discontinuation  of study  drug); 
treatment with other GLP -[ADDRESS_88420] be 
discontinued immediately. Clarified that patients receiving insulin >14 days for 
management of medical emergencies, as well as those receiving rescue therapy will  be 
excluded from the PP  analysis.  
 Added text in Sections [IP_ADDRESS].1  and [IP_ADDRESS].[ADDRESS_88421]  be properly  documented  in the eCRF.  
 Adde d text in Section  6.8.3  to clarify  that patients  using  chronic  systemic  glucocorticoid 
therapy for >14 days during the treatment period will be excluded from the PP analysis 
and these patients will not be discontinued from the  trial. 
 Deleted text in Section 7.1 that patients stoppi[INVESTIGATOR_81096].  
 Deleted select criteria in Section 7.1.[ADDRESS_88422] not include 
another GLP -1 RA. 
 Added Section 7.1.2 , Permanent Discontinuation from the Study, to Section 7, 
Discontinuation  Criteria,  to help separate  criteria  for discontinuation  of study  drug versus 
discontinuation of study. Clarified that prior to study discontinuation, patient will 
discontinue study drug and will perform end -of-study procedures at an ET visit; during 
the ET visit, the patient will be prescribed an appropriate glucose -lowering  regimen and 
glucose self -monitoring  plan.  
 Clarified in Section 7.1.4  that an inadvertently enrolled patient may be allowed to 
continue treatment with study drug if the investigator and Lilly study physician agree that 
it is safe for the patient to do  so. 
 Added text in Section [IP_ADDRESS]  to include rescue therapy for severe, persistent 
hyperglycemia  as an event  of interest  related  to hyperglycemia.  
 Added text in Section [IP_ADDRESS]  instructing that in patients diagnosed with acute 
pancreatitis, the patient must discontinue therapy with study drug, but will continue in  the 
study on another glucose -lowering  regimen.  
H9X-MC-GBGE(a) Clinical Protocol  Page 77 
LY2189265   
  
 Added  text in Section  [IP_ADDRESS]  instructing  that if study  drug is permanently  discontinued  in 
a patient with a severe or serious allergic reaction, the patient will continue in the study 
on another glucose -lowering  regimen.  
 Added text in Section 9.2 stating that analyses of certain outcomes will be performed on 
the full dataset with censoring (to exclude data collected after initiation of rescue with 
glucose lowering therapy for any reason), and also without censoring as sensitivity 
analyses.  
 Added text in Section 9.3.1  describing that patient disposition will include patients 
entered, randomized/enrolled, completing, discontinuing from study drug early, and 
discontinuing from study early. Re asons for discontinuation from the study and/or study 
drug will be  summarized.  
 Added the definitions for Efficacy Estimand and ITT Estimand in Section 9.4.1  and 
clarified the population for the primary analysis of the primary  outcome  measure.  
 Added a new section, Section [IP_ADDRESS]  to describe the additional analyses for the primary 
outcome  measure.  
 Clarified  additional  analyses  of the key secondary  efficacy  measures  in Section  9.4.2.  
 Clarified in Section 9.5.[ADDRESS_88423] -rescue data  censored.  
 Clarified in Section 9.7.1 that the subgroup analysis will be performed using the efficacy 
estimand described in Section  9.4.1 . 
 Statistical references were added to Section  11. 
 The list of abbreviations was updated in Appendix  1. 
 Minor editorial changes to the text were made to correct typographical  errors.  
H9X-MC-GBGE(a) Clinical Protocol  Page 78 
LY2189265   
  
Revised Protocol Sections  
 
1. Synopsis  
 
Statistical Analysis:  
 
The primary analysis population will be the intent -to-treat (ITT) population, defined as all patients randomized who 
have taken at least [ADDRESS_88424] number of measurements (HbA1c, percent to goal in HbA1c, FBG, and body weight) will also be evaluated 
in the Per Protocol population.  
3. Objectives and  Endpoints  
 
Secondary  
Key secondary efficacy objectives (controlled for type 1 
error) are to compare dulaglutide 1.5 mg and 0.75 mg to 
placebo at 24 weeks  
 
 
 
 
 
Other secondary efficacy objectives are to compare 
dulaglutide 1.5 mg and 0.75 mg to placebo at 24 weeks  
 
 
 
 
 
 
Secondary safety objectives are to compare dulaglutide  
1.5 mg and 0.75 mg to placebo at 24 weeks   
 Proportion of patients with HbA1c target values 
of <7.0% at 24  weeks  
 The change in FBG (central laboratory) from 
baseline to 24  weeks  
 The change in body weigh t from baseline to 
24 weeks  
 
 
 Proportion of patients with HbA1c target values 
of ≤6.5% at 24  weeks  
 The change in 6 -point SMPG profile from 
baseline to 24  weeks  
 The change in fasting glucagon from baseline 
to 24  weeks  
 
 
Incidence of:  
 Treatment -emergent adverse events  (TEAEs)  
 Early discontinuations due to  AEs 
 Adjudicated cardiovascular and pancreatic  AEs 
 Thyroid neoplasms  AEs 
 AEs related to kidney failure,  eGFR  
 Systemic hypersensitivity  AEs 
 Local injection site  reactions  
 The change in systolic and diastolic blood 
pressure, heart rate, and lipi[INVESTIGATOR_81059] 
24 weeks  
 Incidence and rate of hypoglycemic  epi[INVESTIGATOR_1841]  
 Ketoacidosis, and discontinuation due to 
initiation of rescue therapy for severe persistent 
hyperglycemia   Note: Deletions have been identified by [CONTACT_58001] . 
Additions have been identified by [CONTACT_81152] . 
H9X-MC-GBGE(a) Clinical Protocol  Page 79 
LY2189265   
  
 
4.1. Overview of Study  Design  
Study Period III:  Randomization and Treatment Period (Visits 5 through 11)  
Patients who develop persistent, severe hyperglycemia based on pre -specified thresholds (see 
Section [IP_ADDRESS]) will continue administering discontinue study drug and study and will receive a 
new glucose -lowering intervention (rescue) based on the clinical judgment of the investigator. 
These patients, as well as those who receive rescue therapy after discontinu ation of e study drug 
due to an AE or any other reason s, will be asked to perform all study visits to collect planned 
efficacy and safety measurements.  
Those patients who are unable or unwilling to continue in the study because of an AE (see 
Section 7.1.2 for details ) or any other reason, will perform an early termination (ET) visit as their 
final study visit (for procedures at the ET visit, see the Schedule of Activities [Appendix 2]). If 
the patient is discontinuing during an unscheduled visit, that visit should be performed as the ET 
visit.  If the patient is discontinuing during a scheduled visit, that visit should be considered the 
ET visit.  
4.3. Scientific Rationale for Study  Design  
This trial is designed to be consistent with recommendations provided in a positi on statement of 
the American Diabetes Association and the European Association for the study of Diabetes 
“Management of Hyperglycemia in Type 2 Diabetes: A Patient -Centered Approach” (Inzucchi et 
al. 2015). Placebo comparator was chosen because it will ena ble characterization of efficacy and 
safety effects of dulaglutide when added to existing therapy with SGLT2 inhibitors, with or 
without metformin. Compared to a design which utilizes active comparator, comparison to 
placebo will allow assessment of the ef fect attributable to dulaglutide alone, which is of 
importance especially for the safety aspect of the combined use. The results are expected to 
enable physicians to choose patients suitable for the combination therapy in the clinical setting. 
To protect t he safety of patients in the placebo arm who will enter Study GBGE with HbA1c 
above the <7% target, several design features are introduced for this purpose: (a) short trial 
duration (24 week -long treatment period), (b) exclusion of patients considered to h ave 
unacceptably high baseline HbA1c (>9.5%), and (c) additional glucose -lowering intervention 
(rescue) discontinuation of for patients with unacceptably high glycemia during the treatment 
period.  
5.2. Exclusion  Criteria  
[12] have been treated with ANY othe r OAMs (other than SGLT2 inhibitor s and 
metformin), GLP -1 RA, pramlintide or insulin 3 months prior to study entry, 
or between study entry and Visit 5 ; or initiate metformin between study entry 
and Visit 5 ; short -term use of insulin for acute care (≤14 day s) during the 3 - 
month period prior to entry is not exclusionary;  
H9X-MC-GBGE(a) Clinical Protocol  Page 80 
LY2189265   
  
 
[IP_ADDRESS].  Management of Patients with Severe, Persistent Hyperglycemia during  the 
Treatment  Period  
An additional therapeutic intervention should be considered in patients who develop persistent, 
severe hyperglycemia after randomization based on the following criteria:  
a) Average daily PG from the 4 -point SMPG profile >240 mg/dL over at least a [ADDRESS_88425] 4 weeks postrandomization;  or 
b) Average daily PG >200 mg/dL over a [ADDRESS_88426] an acute conditio n causing severe hyperglycemia. The 
investigator will decide in consultation with the patient on an appropriate glucose -lowering 
intervention (rescue) after considering relevant clinical criteria. Other GLP -[ADDRESS_88427] not be 
included in the rescue interven tion. Patients who require receive a new intervention will should 
also stop the continue administering study drug for the remaining period in the trial and will be 
discontinued from the study . The investigator will decide in consultation with the patient on an 
appropriate glucose -lowering regimen to be used after the study completion.  
6.8.1.   Antihyperglycemia Medications  
The only glucose -lowering agents that are allowed 3 -months prior to study  entry and during the 
study are study drug and concomitant SGLT2 inhibitors and metformin. In addition, short -term 
insulin use for management of medical emergencies is allowed prior to study entry and after 
randomization (Visit 5), but not during screening  and lead -in/stabilization (Sections 5.1 and 5.2). 
Rescue therapy with other glucose -lowering agents, including insulin, may be medically 
indicated in certain situations after randomization. These situations are described in Section 
[IP_ADDRESS] (severe, persis tent hyperglycemia) and in Section 7.1.1 (early discontinuation of study 
drug).  If any such situation occurs, the patient may be treated with any locally -approved  
glucose -lowering agent, except other GLP -[ADDRESS_88428] be differentiated from short -term use of insulin therapy for medical emergencies when 
reported in the eCRF.  
Patients who receive any glucose -lowering agents 3 months prior to entry or during the  screening 
or lead -in/stabilization periods, other t han those allowed, will not be eligible for further 
participation in the trial. The patients not using metformin prior to study entry (Visit 1) are not 
allowed to initiate this therapy between study entry and Visit 5. Patients who violate this 
requirement will be considered as ineligible and will be discontinued from further participation 
in this  trial. 
If any new glucose -lowering medication is initiated after randomization at Visit 5, other than 
rescue therapy or short -term use of insulin for medical emerg encies, the patient will be required 
to immediately discontinue the medication and the appropriate study deviation report will be 
generated. Any such violation of the protocol that lasted longer than 14 days will exclude the 
patient from the Per Protocol ( PP) population. Patients who refuse to discontinue non -study  
H9X-MC-GBGE(a) Clinical Protocol  Page 81 
LY2189265   
  
 
medications  initiated  during  the treatment  period  will be immediately  discontinued  from  the trial. 
Patients who receive insulin therapy for management of medical emergencies >14 days as well 
as those who receive rescue therapy, will also be excluded from the PP  population.  
[IP_ADDRESS].1.  SGLT2  Inhibitors  
After randomization, dose adjustment or discontinuation of SGLT2 inhibitors is allowed under 
the following circumstances:  
 in situations that require short -term treatment interruption consistent with the product 
labeling for each respective  country;  
 in situations that require dose adjustment or discontinuation due to contraindications per 
country -specific label, for example, in t he case of reduced  eGFR;  
 in the case of increased  hypoglycemia  risk during  the treatment  period  (as described  in 
Section  [IP_ADDRESS]).  
Dose reduction/discontinuation of SGLT2 inhibitors during the trial should be properly 
documented.  
In patients who require re scue therapy, dose increase of SGLT2 inhibitors is allowed, but the 
dose and the reason for change must be properly documented in the eCRF.  
[IP_ADDRESS].2.  Metformin  
Dose adjustment or discontinuation of metformin is allowed after randomization under the 
following circums tances:  
 in situations that require short -term treatment interruption in line with the product 
labeling for each respective  country;  
 in situations  that require  dose adjustment  or discontinuation  due to contraindications  per 
country -specific label, for example, in the case of reduced eGFR;  
 in the case of increased  hypoglycemia  risk during  the treatment  period  (as described  in 
Section  [IP_ADDRESS]).  
Dose reduction/discontinuation of metformin during the trial should be properly docu mented.  
In patients who require rescue therapy, dose increase or initiation of metformin is allowed, but 
the dose and the reason for change/initiation must be properly documented in the eCRF.  
6.8.3.   Systemic Glucocorticoids  
Chronic systemic glucocorticoi d therapy (with the exception of topi[INVESTIGATOR_2855], intraocular, intra - 
articular, or intranasal preparations) is exclusionary if used >14 consecutive days during the 
1-month period before study entry or between study entry and randomization at Visit 5. This  
therapy  is not allowed during the treatment period and patients who require >[ADDRESS_88429] immediately will not be included in the PP analysis be discontinued . 
H9X-MC-GBGE(a) Clinical Protocol  Page 82 
LY2189265   
  
 
7.1. Discontinuation from Study  Treatment  
Study drug may be interrupted temporarily or discontinued permanently. Those patients who 
stop the study drug permanently will also be immediately discontinued from the study.  
7.1.1.  Permanent Discontinuation from of Study Treatment and Study  
Patients will be permanently discontinued from study drug and from the study in the following 
circumstances:  
 For inadvertently  enrolled  patients  for whom  it was determined  that continued  treatment 
with study drug would not be medically appropriate (see Sec tion 7.1.3);  
 Exclusion Criterion Criteria [11], [31], [32], or [34] through and [38] develop(s),  after 
randomization (see Section  5.2); 
 The patient requires a new intervention due to severe, persistent hyperglycemia  (Section 
6.6.1);  
 The patient is diagnosed by [CONTACT_81153];  
 A patient is diagnosed with C -cell hyperplasia or medullary thyroid carcinoma after 
randomization;  
 If a patient develops an eGFR <30 mL/min/1.73m 2 as calculated by  [CONTACT_9289]-EPI; 
 If the patient  or the patient’s  designee,  for example,  legal  guardian,  requests  to be 
withdrawn from study  drug;  
 If the investigator or sponsor decides that the patient should be withdrawn from study 
drug; if the sponsor decides to permanently discontinue study treatment because of an 
SAE or a clinically significant laboratory value, Lilly or its designee should be a lerted 
immediately [see Section  8.2.1]);  
 The patient requires >14 days of therapy with systemic  glucocorticoids;  
 A non -study glucose lowering agent is initiated, except for short -term insulin therapy  for 
medical  emergencies,  and the patient  refuses  to discontinue  this medication;  
 A female patient becomes  pregnant;  
 An investigator,  site personnel  performing  assessments,  or patient  is unblinded;  
 Enrollment in any other clinical trial involving an investigational product or  enrollment 
in any other type of medical research judged not to be scientifically or medically 
compatible with this  study.  
 Investigator  Decision  
o the investigator decides that the patient should be discontinued from the  study  
o if the patient, for any reason, requires treatment with another therapeutic agent 
that has been demonstrated to be effective for treatment of the study  indication, 
discontinuation  from  the study  occurs  prior  to introduction  of the new agent  
 Patient Decision  
o The patient or the patient’s designee, for example, parents or legal  guardian, 
requests to be withdrawn from the  study  
 Sponsor  Decision  
H9X-MC-GBGE(a) Clinical Protocol  Page 83 
LY2189265   
  
 
o Lilly or its designee stops the study or stops the patient’s participation in the study 
for medical, sa fety, regulatory, or other reasons consistent with applicable laws, 
regulations, and good clinical practice  (GCP)  
 Adverse  Event  
o If the investigator decides that the patient should be withdrawn because of an 
SAE (other than those listed above) or a clinical ly significant laboratory value, the 
investigational product is to be discontinued and appropriate measures are to be 
taken. Lilly or its designee is to be alerted immediately. Refer to Adverse Events 
(Section  8.2). 
 Discontinuation of the investigational p roduct for abnormal liver tests should be 
considered  by [CONTACT_81119]  a patient  meets  one of the following  conditions 
after consultation with the Lilly designated medical  monitor:  
o ALT  or aspartate  aminotransferase  (AST)  >8X upper  limit  of normal  (ULN)  
o ALT or AST >5X ULN for more than [ADDRESS_88430]  >3X ULN  and total bilirubin  level  (TBL)  >2X ULN  or prothrombin 
time >1.5X  ULN  
o ALT or AST >3X ULN with the appearance of fatigue, nausea, vomiting, right 
upper -quadrant  pain or tenderness,  fever,  rash,  and/or  eosinophilia  (>5%)  
o Alkaline phosphatase (ALP) >3X  ULN  
o ALP >2.5X ULN and TBL >2X  ULN  
o ALP >2.[ADDRESS_88431] with the appearance of fatigue, nausea, vomiting, right upper - 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%)  
Patients who discontinue the study early will have end -of-study procedures performed (ET visit) 
as shown in the Schedule of Activities (Appendix 2). At the ET visit, the investigator will 
prescribe an appropriate antihyperglycemia regimen and SMPG monitori ng plan to be followed 
after completion of the study.  
Those patients who stop the study drug permanently will receive another glucose -lowering 
intervention (rescue) and will continue participation in the trial according to the protocol, to 
collect all plan ned efficacy and safety measurements. The rescue intervention must not include 
another GLP -1 RA.  
7.1.2.  Permanent Discontinuation from the  Study  
Every attempt should be made to keep patients in the trial irrespective of their adherence to 
treatment with study dru g in order to minimize the amount of missing data and to enable 
assessment of study objectives as planned by [CONTACT_4690]. Patient discontinuation from 
the study early may be warranted in the following situations for ethical or legal reasons:  
 Exclusi on Criterion  [11] 
 When a female patient becomes  pregnant;  
H9X-MC-GBGE(a) Clinical Protocol  Page 84 
LY2189265   
  
 When a patient is enrolled in another clinical trial involving an investigational product or 
is enrolled in any other type of medical research judged not to be scientifically or 
medically compatible with this  study.  
Patients may also discontinue from the study due to:  
 Sponsor or Investigator  Decision  
o If Lilly or its designee stops the study or if Lilly or the investigator stops t he 
patient’s participation in the study for medical, safety, regulatory, or other reasons 
consistent  with applicable  laws,  regulations,  and good  clinical  practice  (GCP)  
 Patient Decision  
o The patient  or the patient’s  designee,  for example,  legal  guardian,  requests  to be 
withdrawn from the  study  
Prior to early study discontinuation, the patient will discontinue study drug and will have end -of- 
study procedures (ET visit) performed as shown in the Schedule of Activities (Appendix 2).  
During the ET visit the p atient will be prescribed an appropriate glucose -lowering regimen and 
glucose self -monitoring plan.  
7.1.4. Discontinuation of Inadvertently Enrolled Patients  
If the sponsor or investigator identifies a patient who did not meet enrollment criteria and was 
inadvertently enrolled, a discussion must occur between the sponsor CRP and the investigator to 
determine if the patient may continue in the study. If both agr ee it is medically appropriate to 
continue, the investigator must obtain documented approval from the sponsor CRP to allow the 
inadvertently enrolled patient to continue in the study with or without treatment with 
investigational product. An inadvertently enrolled patient may be allowed to continue treatment 
with study drug only if the principal investigator [INVESTIGATOR_81097].  
[IP_ADDRESS].  Hypoglycemia and  Hyperglycem ia 
Events of interest related to hyperglycemia ( rescue therapy for severe, persistent hyperglycemia, 
per criteria specified in Section [IP_ADDRESS], and ketoacidosis) will be collected during the trial to 
assess the risk of extreme disbalance in glycemic contro l. 
[IP_ADDRESS].  Pancreatitis  
If acute pancreatitis is suspected, appropriate laboratory tests (including levels of pancreatic 
amylase and lipase) should be obtained via the central laboratory (and locally, if needed).  
Imaging studies, such as abdominal CT scan with or without contrast, MRI, or gallbladder 
ultrasound, should be performed. If laboratory values and/or abdominal imaging supports the 
diagnosis of acute pancreatitis, the patient must discontinue therapy with investigational product 
but will continue in the st udy on another glucose -lowering regimen (see Section 6.8.1 and 
Section 7.1.1 for details on rescue intervention). and will also be discontinued from the study.  
The most appropriate diabetes therapeutic regimen will be decided by [CONTACT_093], based on  
H9X-MC-GBGE(a) Clinical Protocol  Page 85 
LY2189265   
  
 
the patient’s clinical status. A review of the patient’s concomitant medications should be 
conducted to assess any potential causal relationship with pancreatitis.  
[IP_ADDRESS].  Allergic/Hypersensitivity  Reactions  
All allergic or hypersensitiv ity reactions will be reported by [CONTACT_81127], if 
any serious criterion is met, as SAEs. Additional data, such as type of reaction and treatment 
received, will be collected on any AEs or SAEs that the investigator deems related to stu dy drug 
via a CRF created for this purpose.  Study drug should be temporarily interrupted in any 
individual suspected of having a severe or serious allergic reaction to study drug (Section 7.1.2). 
Study drug may be restarted when/if it is safe to do so, in  the opi[INVESTIGATOR_871]. If study 
drug is permanently discontinued, the patient will receive another glucose -lowering treatment, 
judged by [CONTACT_81128]’s clinical status, and will 
continue in the trial to  collect all planed efficacy and safety measurements be discontinued from 
the trial (see Section 6.8.1 and Section 7.1.1).  
9.2. General Statistical  Considerations  
Analyses of certain efficacy outcomes (HbA1c, percent to goal in HbA1c, FBG, body weight) 
and hypoglycemia will be performed on the full dataset with censoring as primary (ie, to exclude 
data collected after initiation of rescue with glucose -lowering thera py for reasons described in 
Section [IP_ADDRESS], Section 6.8.1, and Section 7.1.1). These same analyses will also be performed 
without censoring post rescue data as sensitivity analyses.  
9.3.1.   Patient Disposition  
Frequency counts and percentages of all pati ents entered, randomized/enrolled, completing, 
and/or discontinuing from the study drug early , and discontinuing from the study early will be 
presented for each of the treatment groups. The reasons for discontinuation from the study 
and/or study drug will be summarized by [CONTACT_1570]. A summary of discontinuations will 
also be presented by [CONTACT_765].  
9.4.1.  Primary Outcome Measure and Analyses  
The primary outcome is an efficacy estimand defined as the difference in HbA1c mean change 
from baseline to [ADDRESS_88432] -rescue data censored (excluded). The 
primary hypothesis of interest in this placebo -controlled study is whether dulaglutide has 
superior efficacy compared to placebo, in patients already treated with SGLT2 inhibitors, 
without con founding with rescue therapy.  
[IP_ADDRESS].  Additional Analyses of the Primary  Outcome  
The primary analysis model, MMRM, will be repeated using the PP population to check the 
sensitivity of the analysis. If the conclusion differs from that of the ITT population, the dat a and 
analyses will be further investigated. The secondary analysis model will be an ANCOVA for 
HbA1c change from baseline to 24 weeks (Visit 11), using a similar model as described above 
with treatment, country, SGLT2 inhibitor dose (“low” versus “high”),  and metformin use (“yes”  
H9X-MC-GBGE(a) Clinical Protocol  Page 86 
LY2189265   
  
 
versus “no”) as factors and baseline HbA1c as a covariate. Missing endpoints will be imputed 
with the LOCF using postbaseline data only.  
To investigate departure from the Missing At Random (MAR) assumption for the primary 
analysis that excludes post -rescue data, a sensitivity analysis using a particular missing not at 
random (MNAR) assumption will be performed. Specifically, a placebo multi ple imputation 
(pMI) will be performed (Ayele et al. 2014), which assumes that the drug effect in missing data 
and post -rescue data in both the placebo arm and dulaglutide arm was like the observed effect in 
the placebo arm (excluding post -rescue data). Th is is essentially the “copy reference” approach 
as described in Carpenter et al. 2013. This approach is in essence assuming that the drug effect 
will decay over time, in accordance with the correlation structure implied by [CONTACT_26739]. Data 
imputed this way w ill be analyzed with the same MMRM model as the primary analysis. This 
particular MNAR assumption can be viewed as a “worst reasonable case” assessment of the 
efficacy estimand, or as an effectiveness estimand that assumes patients with missing data or 
rescued patients received no drug benefit after dropout or rescue.  
Also of interest is the effectiveness/treatment regimen estimand that evaluates the difference in 
mean HbA1c change from baseline to 24 weeks in the ITT population regardless of treatment 
discontinuation or use of rescue therapy (ITT estimand). Therefore as a supportive analysis, 
MMRM will be performed on the ITT population with all post -rescue data up to the primary 
endpoint of 24 weeks included.  
For both the efficacy estimand (missing data an d post -rescue data both considered as missing), 
and the ITT estimand (post -rescue data not treated as missing), a tippi[INVESTIGATOR_81080] a MAR assumption. However, prior to 
analysis, in the dulag lutide arm the imputed values will be replaced by [CONTACT_81138]. Multiple values of delta will be tried until the value at which the conclusion from the 
MMRM analysis changes.  
9.4.2.  Secondary Outcome Measures and  Analyses  
The primary analysis model, MMRM, will be repeated using the PP population to check the 
sensitivity of the analysis. If the conclusion differs from that of the ITT population, the data and 
analyses will be further investigated. The secondary analysis model  will be an ANCOVA for 
HbA1c change from baseline to 24 weeks (Visit 11), using a similar model as described above 
with treatment, country, SGLT2 inhibitor dose (“low” vs. “high”), and metformin use (“yes” vs. 
“no”) as factors and baseline HbA1c as a covar iate. Missing endpoints will be imputed with the 
LOCF using postbaseline data only.  
The key secondary continuous efficacy measures will also be analyzed using both models , the 
MMRM and the ANCOVA with LOCF models described above (with and without censoring  
data collected after initiation of rescue intervention) . Analysis of other secondary efficacy 
measures that are continuous variables, except glucagon (for glucagon, see Section 9.5.6), will be 
performed using MMRM on the ITT population. There will be no m ultiplicity adjustment for 
pairwise comparisons.  The MMRM and ANCOVA models will include the model terms  given  
H9X-MC-GBGE(a) Clinical Protocol  Page 87 
LY2189265   
  
 
for the previously described primary analysis model with the addition of the HbA1c strata 
(≤8.0%, >8.0%).  
For percentages of pa tients achieving target HbA1c of <7.0% (including exploratory composite 
endpoints with body weight and hypoglycemia) or ≤6.5% at [ADDRESS_88433] -rescue data excluded (considered missing), and separately 
with all post -rescue data included. In addition, an analysis of percent age of patients on HbA1c 
targets will be performed where patients who have been rescued or have no post -baseline data 
being considered (imputed) as not having achieved the target.  
9.5.3.  Hypoglycemic  Epi[INVESTIGATOR_81081] [IP_ADDRESS] contains definitions of categories of hypoglycemia. A listing of individual 
hypoglycemic epi[INVESTIGATOR_81082]. Summary reports will include both 
incidence and rates of hypoglycemia for the ITT population (with post -rescue d ata censored, and 
without post -rescue data censored) . Hypoglycemia will be categorized as “documented 
symptomatic,” “asymptomatic,” “probable,” “severe,” or “nocturnal,” and for all events 
combined, “total hypoglycemia.” Only “documented symptomatic” and “ total hypoglycemia” 
will be analyzed inferentially.  
9.5.4.  Hyperglycemic  Epi[INVESTIGATOR_81085] (if appropriate) will be provided for events of severe, persistent 
hyperglycemia resulting in discontinuation initiation of rescue therapy , as well as events o f 
ketoacidosis.  
9.7.1.   Subgroup Analyses  
A subgroup analysis will be performed on the primary endpoint using the efficacy estimand and 
the same model as the primary analysis model with an added term for the [ADDRESS_88434] interaction visit - 
by-treatment -by- [subg roup].  
11. References  
Ayele BT, Lipkovich I, Molenberghs G, Mallinckrodt CH. A multiple -imputation -based 
approach to sensitivity analyses and effectiveness assessments in longitudinal clinical trials. J 
Biopharm Stat . 2014;24(2):[ADDRESS_88435] MG. Analysis of longitudinal trials with protocol deviation: a 
framework for relevant, accessible assumptions, and inference via multiple imputation. J 
Biopharm Stat . 2013;23(6):1352 -1371. doi: 10.1080/10543406.2013.834911.  
H9X-MC-GBGE(a) Clinical Protocol  Page [ADDRESS_88436] be completed before processing in the interactive interactive voice web-response 
system (IWRS).  
 
  
Leo Document ID = fc20c2fa -1d5e-4c92-a0fb-ab6970d025b9  
Approver: Honghua H Jiang (AM \C045373) 
Approval Date & Time: 20 -Aug-2015 22:14:37  GMT 
Signature [CONTACT_32869]:  Approved  
 
Approver: David Bradley Woodward (AM \A515116) 
Approval Date & Time: 21 -Aug-2015 19:44:52 GMT 
Signature [CONTACT_32869]: Approved  
 
 Leo Document ID = ec26235b -baf2-4429-a85b-aacb51b3f79f  
Approver: David Bradley Woodward (AM \A515116) 
Approval Date & Time: 02 -Feb-2018 14:15:30 GMT 
Signature [CONTACT_32869]: Approved  